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ABSTRACT
Despite available treatment options, the number of people afflicted by type
2 diabetes has steadily risen for decades. Nearly 90% of the diabetic population
also suffers from obesity and the link between the two diseases is undeniable.
Characterized by rapid expansion of the adipose tissue and improper lipid storage,
the mishandling of lipids by adipose tissue promotes the diabetic state. Excess
lipids, unable to be properly stored, build up in peripheral tissues promoting insulin
resistance and type 2 diabetes. Therapeutic strategies designed to address
adipose tissue lipid handling could represent a promising treatment strategy for
obesity associated type 2 diabetes. Here we investigate the use of polymer
scaffolds made of poly(lactide-co-glycolide) as a way to engineer adipose tissue
lipid metabolism. Implant of scaffolds into the epididymal adipose tissue of mice
leads to glucose and lipid utilization and is attributed to the host response to the
material. This lipid oxidizing effect is enhanced by incorporating resveratrol into the
polymer scaffolds. Importantly, implant of scaffolds protects mice against fat gain
and insulin resistance in a mouse model of obesity associated type 2 diabetes.
Finally, we demonstrate the ability of scaffolds combined with healthy dietary
changes to reverse insulin resistance in a mouse model of obesity associated type
2 diabetes. Taken together, this work demonstrates promise for tissue engineering
strategies designed to address adipose tissue lipid handling as a platform to treat
obesity associated type 2 diabetes.
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CHAPTER 1
INTRODUCTION
1.1.

Defining obesity and its underlying causes.
Clinically obesity is defined as an adult with a body mass index (BMI), an

estimate of body fat content based on the height and mass of the individual, over
301. Obesity is the result of an energy imbalance where caloric intake exceeds
caloric expenditure. The body responds to excess energy intake by storing surplus
calories in the form of lipids (fat) in the adipose tissue (fat tissue)2. The excess
lipid storage, results in the rapid expansion of the adipose tissue, progressing in
severity until the individual’s fat mass has expanded to a point where a clinical
diagnosis of obesity is given.
1.2.

The obesity epidemic and its health and economic burden.
The National Institutes of Health and the Center for Disease Control

estimate that 32.7% of adults in the United States are overweight and 37.9% are
obese as of 20141. These rates have continued to climb throughout the decades,
and it has been projected that half of all U.S. adults will be obese by 20303.
Importantly, obesity is associated with increased incidents of type 2 diabetes,
cardiovascular disease, stroke, dyslipidemia, and certain cancers4. The
comorbidities associated with obesity place a substantial burden on the quality of
life of individuals affected with these conditions. In addition to diminished quality of
life, obesity also has a large economic burden. The healthcare costs for obese

1

individuals has been estimated to be 30% higher than those with normal weight3.
The elevated cost of healthcare combined with the increased prevalence of obesity
resulted in estimates that obesity related healthcare accounted for 27% of the
growth in U.S. healthcare spending from 1987-20013. This rate of spending is
expected to double every decade, rising with the ever increasing population of
obese individuals, with estimates that obesity and its related complications will
account for 16-18% of total U.S. health care expenditure by 20305. Taken together,
the overwhelming prevalence and burdens, both health and economic, associated
with obesity highlight the dire need to understand more about the condition and
develop new and innovative platforms for its treatment.
1.3.

Adipose tissue biology.
The tissue most directly associated with obesity is the adipose tissue, or fat

tissue. For decades the adipose tissue was considered to be an inert tissue whose
only function was to store excess caloric energy in the form of lipids. However,
research over the past decade has revealed a much larger role for the tissue in
whole body metabolism. In addition to the tissue’s storage capabilities, the adipose
tissue functions as an endocrine organ, secreting a variety of hormones, cytokines,
and other factors which function to regulate glucose and lipid metabolism both
locally and in distant tissues6. Examples of important hormones secreted by the
adipose tissue include adiponectin, a hormone which functions to stimulate
glucose uptake and lipid metabolism in distant tissues such as the skeletal muscle7
and leptin, which signals in the hypothalamus to induce satiety8. In addition, levels
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of lipids and fatty acids released from the adipose tissue can also signal in distant
tissues in a similar manner to the hormones described above.
These endocrine functions of the adipose tissue are regulated not just by
the adipocytes (fat cells), the most prevalent cell population in the tissue, but also
the local immune cells that reside within the tissue9. Specifically, adipose tissue
macrophages, the second most prevalent cell population in the adipose tissue,
play a large role in regulating the tissue’s endocrine functions. In healthy adipose
tissue, macrophages express an anti-inflammatory gene profile and have various
functions including efferocytosis (removal of dying or dead cells), lipid buffering,
and angiogenesis9. The importance of healthy interaction between adipocytes and
adipose tissue macrophages is highlighted when it becomes dysregulated in the
obese state, explained further in the subsequent section.
1.4.

The link between obesity and type 2 diabetes.
Out of all comorbidities associated with obesity, the link between obesity

and type 2 diabetes is clearly established. Over 90% of type 2 diabetics also suffer
from obesity10. There is no question that adipose tissue dysfunction constitutes a
mechanistic link between obesity and diabetes11. Healthy adipose tissue serves
as an energy reservoir that expands during overnutrition to store excess calories
as lipids and releases these lipids in response to an energy deficit6. In the obese
state, adipose tissue has a limited capacity to store additional lipids, and this is
especially evident in adipose tissue around internal organs (visceral fat)12. The
excess lipid in the visceral fat causes inflammation, which leads to the influx of
inflammatory macrophages. Lipids are then secreted from the dysfunctional

3

visceral fat and accumulate in the liver and muscle, known as ectopic lipid
deposition,

where

they

cause

insulin

resistance

and

inflammation13–15.

Concurrently, there is a decline in the release of hormones that promote insulin
sensitivity, glucose uptake, and lipid catabolism in peripheral tissues16. This
constellation of maladaptation leads to hyperglycemia, which damages the
cardiovascular system and other vital organs, including the pancreas17,18 which
over time leads to the onset of type 2 diabetes.
1.5.

Current treatment strategies and shortcomings.
The first line of defense when treating obesity associated type 2 diabetes

focuses on lifestyle changes such as diet and exercise. However, many patients
fail to strictly adhere to these lifestyle changes. Reasons for non-compliance are
multifactorial, some of the more commonly cited complaints from patients include
a lack of motivation, failure to see noticeable progress, and the inability to adhere
to therapies due to a physical injury19. Due to these reasons, the success of
lifestyle changes in treating obesity associated type 2 diabetes has been estimated
to be as low as 10%20.
When lifestyle changes fail to achieve adequate glycemic control,
treatments are often supplemented with pharmacological agents designed to lower
blood glucose levels. These pharmacological agents lower blood glucose in a
variety of ways such as lowering hepatic glucose production (metformin)21,
increasing renal excretion of glucose (canagliflozin)22, and stimulating the
pancreas to secrete additional insulin (glipizide)23, however these strategies fail to
address the underlying adipose tissue dysfunction behind the disease.
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Furthermore, it has been estimated that over 50% of patients on current treatment
regimens fail to achieve their glycemic goals which has been attributed to issues
such as poor patient compliance, low bioavailability, and unintended off target
effects cause by systemic administration of pharmacological agents20. Therefore,
novel therapeutic strategies specifically designed to improve adipose tissue health
and storage capacity while addressing the drawbacks of existing therapies could
have a greater chance of success when translated to the clinical setting.
1.6.

Biomaterial scaffolds for tissue engineering.
Tissue engineering is a strategy that combines life sciences with

engineering principles to restore or direct tissue function24,25. Biomaterials are
commonly employed in these techniques as delivery vehicles of therapeutic agents
such as cells, proteins, and small molecules. Poly(lactide-co-glycolide) or PLG is
one of the most popular biomaterials for tissue engineering applications as it is
tolerated well by the body and has gained FDA approval for various therapeutic
applications such as VivitrolÒ, which delivers naltrexone from PLG microparticles
to treat alcoholism and ZoladexÒ, a solid implant of PLG that delivers goserelin
acetate to treat prostate cancer26,27. In the field of tissue engineering, scaffolds
made of PLG have been studied for a wide variety of applications such as bone
regeneration28,29, delivery of islet cells to treat type 1 diabetes30, and modulating
the foreign body response to materials31. However, while PLG scaffolds have been
implanted into the adipose tissue in previous studies30,32, their effects on the
adipose tissue have been left uncharacterized. Therefore, the focus of the
research in this dissertation was to assess the ability of PLG scaffolds to engineer
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the lipid metabolism in the adipose tissue as a therapeutic strategy to treat obesity
associated type 2 diabetes.
1.7.

Design of polymer scaffolds for the correction of obesity associated

adipose tissue dysfunction.
The central hypothesis of this dissertation is that biomaterial scaffolds
implanted into the adipose tissue can be used to increase lipid metabolism in the
tissue, thereby preventing ectopic lipid deposition in peripheral tissues which
drives insulin resistance, providing a novel platform for the treatment of obesity
associated type 2 diabetes. The proposed project will test this hypothesis with a
set of three specific aims designed to (1) demonstrate the efficacy of a polymer
scaffold-based therapy at treating impaired insulin resistance in obesity associated
type 2 diabetes as well as (2) allow understanding of the mechanism of action
behind this approach and (3) understand how this treatment method combines with
healthy lifestyle changes. Anticipated results would establish scaffold-based
therapies as a viable platform for the treatment of obesity associated type 2
diabetes and establish a foundation on which future studies could build off of,
eventually leading to a clinically translatable therapy.
1.7.1 Aim 1: Characterize the effects of poly(lactide-co-glycolide) scaffolds on
adipose tissue function.
In order to gain an understanding of how tissue engineering scaffolds alone
impact adipose tissue function, initial studies were completed on unloaded polymer
scaffolds. Scaffolds used in Aim 1 were composed of poly(lactide-co-glycolide).
This polymer was selected for pilot studies as it has been implanted into the
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adipose tissue for various pre-clinical applications30,32,33. Polymer scaffolds were
implanted into the epididymal adipose tissue of male C57BL/6 mice. Important
read outs were levels of glucose transport proteins both at the implant site and in
distant tissues, as well as local and systemic levels of health promoting hormones,
specifically adiponectin, leptin, insulin, and insulin-like growth factor 1 (IGF-1).
Finally, clinical translatability was assessed using the high fat diet mouse model,
a common pre-clinical model of obesity associated type 2 diabetes. Anticipated
results will provide an understanding of the changes in glucose transport and
adipose tissue function caused by unloaded scaffolds, allowing for the
incorporation of additional agents (e.g. drugs, cells, proteins) to further augment
the therapeutic effects cause by the polymer.
1.7.2 Aim 2: Incorporate resveratrol into polymer matrix for direct delivery to the
adipose tissue in order to promote lipid metabolism.
In order to demonstrate the efficacy of PLG scaffolds as drug delivery
vehicles to the adipose tissue, the naturally occurring polyphenol resveratrol was
incorporated into the matrix of the scaffolds. Resveratrol was selected for this study
as it has shown to have beneficial effects on the adipose tissue including promoting
the oxidation of lipids and fatty acids for fuel34, however it requires high oral
dosages due to its rapid metabolism in the bloodstream35. Direct delivery of
resveratrol to the adipose tissue from PLG scaffolds could improve the
bioavailability of the drug. Similar to Aim 1, experimental read outs were local and
systemic measurements of glucose transport and fat accumulation. Clinical
translation was determined using a high fat diet mouse model of obesity associated
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type 2 diabetes. Anticipated results from this aim demonstrate the therapeutic
efficacy of drug delivery to the adipose tissue from polymer scaffolds. Additionally,
the successful incorporation of resveratrol into the polymer matrix provides a
platform which can be easily translated to other small molecules with
physiochemical properties similar to that of resveratrol.
1.7.3 Aim 3: Assess of the ability of resveratrol loaded scaffolds to combine with
healthy dietary changes.
Often times in the treatment of obesity, pharmacological therapies are
combined with lifestyle changes such as improved diet and exercise. Therefore,
the ability of resveratrol loaded scaffolds to combine with changes in healthy diet
changes and promote healthy adipose tissue function and glucose uptake is
important to understand. To this end, mice were placed on the high fat diet mouse
model prior to administration of resveratrol loaded scaffolds to induce fat gain and
glucose intolerance. Resveratrol loaded scaffolds were then implanted into the
adipose tissue and the mice were returned to a normal diet simulating a healthy
dietary change. Readouts from this study were weight reduction and glucose
intolerance which was assessed as the mice returned from the diseased to healthy
state.
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CHAPTER 2
THE HOST RESPONSE TO POLY(LACTIDE-CO-GLYCOLIDE)
SCAFFOLDS PROTECTS MICE AGAINST DIET INDUCED
OBESITY AND GLUCOSE INTOLERANCE
2.1

Introduction.
The adipose tissue plays an important role in energy homeostasis by storing

excess glucose and dietary lipids as triglycerides and secreting endocrine acting
factors (adipokines) that modulate glucose and lipid metabolism6. Indeed, the
importance of proper adipose tissue function is emphasized by the adverse
metabolic consequences of both its excess (obesity) and its deficiency
(lipodystrophy). In both cases lipids circulate at high levels in the blood stream and
accumulate at undesirable sites, such as muscle and the liver, causing insulin
resistance13–15. Furthermore, there is a decrease in production of health promoting
adipokines16. This constellation of maladaptation impairs glucose tolerance and
causes hyperglycemia, which damages the cardiovascular system and other vital
organs, including the pancreas17,18. The first line of defense, in concert with diet
and exercise, is antidiabetic medications that improve insulin sensitivity or promote
insulin production; however, their side effects hinder drug safety, patient
compliance, and drug effectiveness20.
Rather than treating hyperglycemia with systemic drug administration, a
more pragmatic approach might be to engineer the adipose tissue to improve its
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storage of glucose and lipids or augment its production of adipokines that naturally
promote their metabolism. Polymeric scaffolds are a promising platform to
accomplish these goals as they can be designed to release bioactive factors that
modulate these functions. In this work we investigated porous poly(lactide-coglycolide) (PLG) scaffolds (Fig. 2.1) for drug delivery to the epididymal adipose
tissue of mice. PLG was selected for its established track record as a drug delivery
matrix in several FDA approved devices26,36 and previous work indicating that
porous PLG scaffolds integrate well with the epididymal fat31,32. To our surprise,

Figure 2.1. PLG scaffolds for implant into adipose tissue. (A) Photograph of
scaffold relative to a United States penny. Scanning electron microscope images of a
(B) side and (C) top profile of a scaffold. Scaffolds are 5 mm in diameter, 2 mm in
height, and 98% porous with a pore size ranging between 250 and 500 microns.

we detected a decrease in fasting blood glucose levels in healthy mice that
received PLG scaffolds with no drug payload. In addition, epididymal fat pads with
scaffold implants were significantly smaller compared to controls. Intrigued, we set
out to determine how “empty” scaffolds might modulate blood glucose levels and
fat pad size and if these responses had therapeutic implications. Guiding these
studies was the overarching hypothesis that the increased cellular activity that
occurs during scaffold integration with the host tissue (i.e. the host response) was

10

associated with increased expression of proteins that promote glucose uptake and
that this response was sufficient to mitigate glucose intolerance induced by a high
fat diet.
2.2

Methods.

Scaffold Fabrication.
Poly(lactide-co-glycolide) (PLG) microspheres were prepared as previously
described37. Briefly, PLG (75:25 mol ratio d,l-lactide to glycolide, 0.76 dL/g)
(Evonik) was dissolved in dichloromethane to make a 6% (w/w) solution, which
was then emulsified in 1% poly(vinyl alcohol) to create microspheres. The
microspheres were collected by centrifugation, washed with deionized water, and
lyophilized overnight. Microspheres were combined in a 1:30 mass ratio with NaCl
particles 250–500 µm in diameter. The mixture was pressed in a steel die at 1000
pounds per square inch (psi) and gas-foamed using 800 psi CO2 gas at room
temperature. The salt porogen was removed by washing in deionized water.
Complete salt removal was confirmed by scaffold weight and microscopy. Prior to
implantation, scaffolds were washed in 70% ethanol and rinsed in sterile
phosphate buffered saline (PBS; Life Technologies).
Scanning Electron Microscopy and Histology.
Scanning electron microscopy was performed using standard techniques.
Briefly, scaffolds were placed on aluminum SEM stubs coated with carbon
adhesive tape. Scaffolds were then sputtered with gold for 1 minute 3 times to
ensure complete coating. Images were taken on a TESCAN Vega3 scanning
electron microscope at 10kV. For histology, epididymal fat pads were excised,
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fixed in 4% paraformaldehyde for 24 hours, and embedded into paraffin blocks. 7
µm sections were cut from each block and stained with hematoxylin and eosin
(H&E). Analysis of adipocyte size was performed using Image J’s MRI Adipocyte
tool.
Animals.
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks
of age. All animals were housed with ad libitum access to water and food in a
temperature-controlled room with a 12:12 h light:dark. All procedures were
performed in accordance with NIH Guidelines for Care and Use of Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of South Carolina. Mice were allowed to acclimate for two weeks prior
to study.
Scaffold Implantation.
Mice received scaffold implant into the epididymal fat as previously
described. Briefly, mice were anesthetized with a 2% mixture of isoflurane and
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile
fashion. Following a lower abdominal midline incision, scaffolds were wrapped in
each epididymal fat pad. The abdominal wall was then closed with a running stitch,
and the skin was closed with wound clips. Lean animals received one scaffold per
fat pad. Mice challenged with high fat diet received two scaffolds per fat pad.
Food Intake Measurements.
Food was weighed at the beginning and end of each week and the total
grams of food consumed was calculated. To obtain kcal per mouse, weight of food

12

consumed was normalized by the number of mice in the cage and multiplied by
the calorie density in the food (3 kcal/gram).
Enzyme-Linked Immunosorbent Assays (ELISA).
Blood was collected from mice fasted for 6 hours retro-orbitally into EDTA
coated tubes, spun down at 10,000 g, and plasma was isolated. Adipose tissue
was homogenized in RIPA buffer (Thermo Scientific) supplemented with protease
inhibitor cocktail (Thermo Scientific), phospho-stop (Roche), and phenylmethane
sulfonyl fluoride (Sigma). Following homogenization, protein was isolated via
centrifugation at 18,000 g for 45 minutes. ELISA was used to determine mg of
analyte per mg of adipose tissue; results were then normalized to naïve controls.
Insulin ELISA kit was purchased from ALPCO. All other ELISA kits were purchased
from R & D Systems.
Immunoblotting.
Both adipose tissue and gastrocnemius protein was isolated as described
in the section above. Protein concentrations were determined using a BCA assay
(Thermo Scientific). Lysates (30 ug adipose tissue, 100 ug gastrocnemius) were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
were then transferred to a nitrocellulose membrane (GE Healthcare Life Sciences)
and incubated with appropriate antibodies. Secondary antibody was a horseradish
peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) grown in goat
(Abcam). Proteins were then visualized using SuperSignal West Pico substrate
(Thermo Scientific). Antibodies to Glut1, total Akt, phospho-Akt ser 473, and
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GAPDH were purchased from Cell Signaling Technology (1:1000 dilution). The
antibody for Glut4 was purchased from Sigma Aldrich (1:1000 dilution).
Clodronate Liposome Injections.
Clodronate liposomes (Liposoma B.V.) were injected into the intraperitoneal
cavity. 100 uL was administered at a concentration of 5 mg/mL. Liposomes were
warmed to room temperature and mixed thoroughly before injection. After 48
hours, mice received scaffold implants as described above. A control group of mice
also received the scaffold implant without an injection of clodronate liposomes.
Flow Cytometry.
Following euthanasia, epididymal fat pads were excised and washed in ice
cold PBS. Fat pads were shredded, digested in collagenase (Liberase TL, Roche),
and passed through a 100 µm filter to remove debris. The stromal vascular fraction
was separated by centrifugation and washed in MACS buffer (PBS, 0.5 mM EDTA,
30% BSA). Before applying antibody panels, samples were incubated with an antiCD16/32 antibody to reduce nonspecific binding. After antibody incubation,
samples were washed in MACS buffer, fixed, and analyzed using a FACS Aria flow
cytometer (BD Biosciences). Total number of macrophages (F4/80+ CD11b+ cells)
in each sample was calculated by adding Bang’s labs Flow Cytometry Absolute
Count Standard, prior to data acquisition. Compensation and data analysis were
completed using FlowJo software (Treestar). FMOs with isotype controls were
used to determine specific antibody signal. The gating scheme used in the flow
cytometry analysis is outlined in Supplemental Figure 2.10.
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High Fat Diet Feeding.
After two weeks of acclimation, mice were placed on a 60% high fat diet
(Research Diets D12492) while a control group was kept on a normal diet (Teklad
8904). On caloric basis, the high-fat diet consisted of 60% fat from lard, 20%
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet
contained 12% fat, 66% carbohydrate, and 22% protein (total 3.0 kcal/g). Mice
were kept on the high fat diet for one week prior to scaffold implantation and
remained on the diet for the remainder of the experiment.
Duel-Energy X-ray Absorptiometry (DEXA).
Body composition was assessed using DEXA scans (Lunar PIXImus). Each
mouse was anesthetized for the duration of the procedure (5 min) by exposure to
2% isoflurane-oxygen gas via nose cone. Each mouse was placed on the scanner
bed in the prone position, with the limbs and tail stretched away from the body.
One scan per mouse was performed and analyzed with PIXImus software (Lunar).
The head was excluded from calculation using a manual ROI. The PIXImus was
calibrated with an aluminum/Lucite phantom (corresponding to bone mineral
density = 0.0592 g/cm2 and 12.5% fat) on each day of testing according to the
manufacturer's instructions.
Intraperitoneal Glucose Tolerance Test (IPGTT).
Mice were fasted for 6-hours before receiving injections of D-glucose into
the intraperitoneal cavity. Glucose administered was normalized to the lean mass
calculated via a DEXA scan that was conducted one-day prior (2 g glucose per kg
lean mass). Blood samples were collected via a tail vein prick at 0, 15, 30, 60, 90,
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and 120 minutes after glucose administration. Glucose measurements were
obtained using a handheld glucose meter (Accu-Chek Nano, SmartView).
In-vivo glucose uptake assay.
Mice were implanted with one scaffold into either the left or right epididymal
fat pad. The contralateral fat pad served as an internal control. In addition, naïve
mice were included in the experiment for comparison. The glucose uptake assay
was performed two weeks after scaffold implant. Mice were fasted 6 hours prior to
the start of the experiment. 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2deoxyglucose (2-nbdg) (Cayman Chemical) was reconstituted in sterile PBS at a
concentration of 10 mg/mL. Each mouse received 100 mg/kg of 2-nbdg via an
intraperitoneal injection. After two hours, tissues were harvested and washed
thoroughly in PBS before imaging on an IVIS Lumina III at 480/570 nm
(excitation/emission). Manual ROIs were drawn around each tissue. The
measurements are presented as the total radiant efficiency from a tissue
normalized by that tissue’s weight.
Statistical Analysis.
Data are plotted as mean ± standard deviation. Statistical analyses were
conducted using GraphPad Prism version 7. P values less than 0.05 were
considered significant. Two groups were compared using an unpaired two tailed ttest. Groups of three or more were compared using a one-way ANOVA with
Tukey’s multiple comparison test. Two or more groups over time were compared
by two-way ANOVA with Tukey’s multiple comparisons test.
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2.3

Results.

Implant of PLG scaffolds into the epididymal adipose tissue lowers fasting blood
glucose.
A hallmark of a promising diabetes therapy is its ability to lower blood
glucose levels. We found that PLG scaffolds caused a significant decrease in

Figure 2.2. Impact of scaffold implant on C57BL/6 mice. (A) Fasting blood glucose
measured 2 weeks after implant. Sham controls received implant procedure, but no
scaffold. (B-E) Plasma insulin, adiponectin, leptin, and IGF-1 measured 2 weeks after
implant. (F) Percent change in body weight from the day of scaffold implant over time.
(G) Weekly kcal intake per mouse over the 2-week experiment. (H) Intraperitoneal
glucose tolerance test completed 2 weeks after implant and (I) area under the curves.
Statistics calculated using a one-way ANOVA with Tukey’s multiple comparison test. *
indicates p<0.05 versus naïve, † indicates p<0.05 versus sham. n=3-5 mice per
condition.
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fasting blood glucose when implanted into the epididymal fat of C57BL/6 mice (Fig.
2.2A). The drop in fasting glucose occurred without significant changes in plasma
insulin (Fig. 2.2B), adiponectin (Fig. 2.2C), leptin (Fig. 2.2D), or IGF-1 levels (Fig.
2.2E), which are hormones that promote glucose uptake38–41. The implant
procedure alone (sham), which is a major surgery, also lowered fasting blood
glucose; however, the scaffold group’s blood glucose was significantly lower
compared to the sham group. The surgery also led to fluctuations in weight gain
(Fig. 2.2F) and an increase in food intake (Fig. 2.2G) compared to age and sex
matched mice that were unmanipulated (naïve), but we did not detect significant
differences in weight or food intake between the sham and scaffold groups. We
suspect increased food consumption was due to increased energy requirements
to recover from the surgery42. The decreased fasting blood glucose led us to
investigate if whole-body glucose tolerance was affected, but we did not detect a
difference in the area under the curve between any of the groups following an
intraperitoneal glucose tolerance test (Fig. 2.2H-I). Taken together, these results
indicate that scaffold implant lowers fasting blood glucose levels and suggests this
effect is not due to changes in the plasma levels of hormones that promote glucose
uptake.
Scaffolds promote elevated glucose uptake at the implant site.
Mice with scaffolds exhibited lower fasting blood glucose levels than naïve
mice (Fig. 2.2A). Thus, we investigated in fasted mice how scaffolds impact
glucose uptake at the implant site (epididymal fat) and in other tissues. To
accomplish this, we fasted mice for 6 hours and then injected them
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Figure 2.3. Effect of scaffold implant on glucose uptake in tissues from fasted
mice. (A) Fluorescent images of tissues that are sites of glucose uptake. iWAT and
eWAT indicate epididymal and inguinal fat pad, respectively. The top panel is
representative of naïve (unmanipulated) mice. The bottom panel is representative of
mice implanted with a scaffold into an epididymal fat pad 2 weeks prior to the
experiment. The contralateral epididymal fat pad was not manipulated. Mice were
fasted for 6 hours and then injected with 2-nbdg, a fluorescent glucose analogue.
Tissues were harvested two hours later. (B) Quantification of fluorescent signal, which
is indicative of glucose uptake, detected in epididymal fat pads. Statistics calculated
using a one-way ANOVA with Tukey’s multiple comparisons test. * indicates p<0.05
compared to naïve, † indicates p<0.05 compared to contralateral. (C) Quantification of
fluorescent signal in the other tissues from panel A. Statistics calculated using an
unpaired t-test. No differences were detected. n=3 mice for naïve and n=6 mice for
scaffold.

intraperitoneally with 2-nbdg, which is a fluorescent tracer for measuring glucose
uptake in tissues43. Two hours after 2-nbdg injection, tissues were harvested for
analysis. Fluorescent images of these tissues are shown in Fig. 2.3A. The top
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panel is representative of a naïve mouse and the bottom panel is representative
of a mouse that received one scaffold into an epididymal fat pad 2 weeks before
the experiment. The contralateral epididymal fat pad was not manipulated.
Strikingly, glucose uptake is most apparent in the immediate vicinity of the scaffold
in epididymal fat (white dotted circle in Fig. 2.3A). Quantitatively, glucose uptake
was increased by 60% in epididymal fat pads with a scaffold compared to the
contralateral control or epididymal fat from naïve mice (Fig. 2.3B). Glucose uptake
was unchanged for all other tissues investigated; however, we did note that all
tissues from the scaffold group tended to have higher glucose uptake compared
to the naïve group except for the spleen (Fig 2.3C). Taken together, the data
suggest that the decrease in fasting blood glucose in mice with scaffolds is due to
enhanced glucose uptake at the scaffold implant site.
Scaffold implant modulates expression of proteins that regulate glucose uptake
within the adipose tissue.
The results of the in vivo glucose uptake assay encouraged us to investigate
molecular mechanisms behind enhanced glucose uptake at the implant site;
therefore, we investigated expression of Glut1 and Glut4, glucose transporters that
can modulate blood glucose levels44,45. Glut4 expression was unchanged in the
epididymal adipose tissue of mice with scaffolds (Fig. 2.4C); however, Glut1
expression was increased threefold (Fig. 2.4B). Glut1 resides on the plasma
membrane of many cell types and is responsible for basal glucose uptake46–48. In
contrast, Glut4 modulates blood glucose levels by translocating from intracellular
stores to the plasma membrane following signaling through the insulin/IGF-1
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pathway. This translocation is maximally facilitated through Akt phosphorylation at
serine 47349,50. Surprisingly, we found that Akt phosphorylation at serine 473 was
significantly decreased in fat pads with scaffold implants (Fig. 2.4D), suggesting
Glut4 may not be involved in lowering fasting blood glucose levels two weeks after

Figure 2.4. Effect of scaffold implant on glucose transporters and Akt signaling
in the epididymal fat and gastrocnemius. Representative western blots and their
quantification for Glut1, Glut4, phosphorylated Akt (s473), and total Akt in the (A-D)
epididymal fat and (E-H) gastrocnemius 2 weeks after implant. Data normalized to
naïve controls. Statistics calculated using an unpaired t-test. * indicates p<0.05 versus
sham. n=3-5 mice per condition. N = naïve, Sh = Sham, Sc = Scaffold.

scaffold implant. To investigate if other tissues distant from the implant site
exhibited changes in glucose transporters or Akt signaling, we repeated our
analysis in the gastrocnemius (Fig. 2.4E-H). Congruent with our findings from the
in vivo glucose uptake assay, which indicated that glucose uptake was unchanged
in the gastrocnemius of mice with scaffold implants, we did not observe differences
in Glut1, Glut4, or pAkt levels between the scaffold and sham groups.
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We next sought to determine possible causes for the decreased levels of
phosphorylated Akt in the epididymal fat implanted with scaffolds. Chronic insulin
or IGF-1 receptor signaling can decrease Akt phosphorylation51 and thus we
investigated expression of insulin and IGF-1 in the tissue. While we did not find
differences in insulin levels in the epididymal fat (Fig. 2.5A), IGF-1 expression was
elevated as early as seven days after scaffold implant and remained elevated

Figure 2.5. Effect of scaffold implant on local expression of proteins that regulate
glucose uptake. (A) Adiponectin, leptin, and insulin protein levels in epididymal fat 2
weeks after implant measured by ELISA. Data normalized to naïve controls. n=5 mice
per condition. (B) IGF-1 protein levels in epididymal fat measured by ELISA at various
time points after scaffold implant. Data normalized to naïve controls. Statistics
calculated using a two-way ANOVA with Tukey’s multiple comparisons test. * indicates
p<0.05 versus sham at the corresponding time point, † indicates p<0.05 versus scaffold
on Day 28. n=5 mice per condition.

after 28 days (Fig. 2.5B). In contrast, adiponectin and leptin levels were not
different between the scaffold and sham groups (Fig. 2.5A). These data indicate
that scaffold implant into the epididymal fat increases Glut1 and IGF-1 expression
and suggest that local glucose uptake through their elevated expression leads to
decreased blood glucose levels.
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Scaffold implant results in remodeling of the adipose tissue that decreases
adipose tissue size.
We next sought to understand why Glut1 is elevated in the adipose tissue
following scaffold implant and began with a histological analysis of the implant site.
Tissue sections from epididymal fat pads 10 days after scaffold implant revealed
cellular infiltration and protein deposition not present in naïve fat pads (Fig. 2.6A
versus 2.6B). The tissue remodeling did not spread throughout the entire fat pad
but localized around irregular shape voids that are pieces of the scaffold dissolved
during tissue processing (Fig. 2.6B). In fact, when inspecting adipose tissue distant
from the implant site we could not detect differences in tissue structure between
naïve adipose tissue and tissue that received scaffolds. That being said, we did
note there was a small, but significant decrease in adipose tissue weight and
adipocyte size in epididymal fat pads with scaffold implants compared to those
from sham mice (Fig. 2.6F-G). Inspection of the implant site at high magnification
revealed giant cells with acidophilic cytoplasm and multiple nuclei were in close
association with pieces of the scaffold (Fig. 2.6C). Patches of fibrous tissue appear
light pink and contain both mononuclear immune cells (circular nuclei) and
fibroblasts (oval nuclei). Finally, vessels containing red blood cells are present
throughout the implant site suggesting the implant environment is integrated with
the host. Glut1 is ubiquitously expressed among cells in the body and is
responsible for the basic supply of cells with glucose52. Glut1 exhibits highest
expression levels in erythrocytes and endothelial cells, but is also found on
macrophages, T cells, fibroblasts and adipocytes53–57. Thus, we conclude that
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Figure 2.6. The effect of scaffold implant on epididymal fat. (A-E) Representative
images of formalin fixed paraffin embedded tissue sections stained with hematoxylin
and eosin. (A) Naïve epididymal fat and (B) epididymal fat 10 days after scaffold
implant; scale bars are 500 µm. (C) Scaffold implant site at day 10; scale bar is 50 µm.
(D-E) Representative images of adipocytes from mice receiving (D) sham surgery and
(E) scaffolds 2 weeks after implant; scale bar is 50 µm. (F) Quantification of adipocyte
area at 2 weeks. Data normalized to naïve; n=3 mice per condition. (G) Weight of
epididymal fat at 2 weeks. Data normalized to naïve. n=5 mice per condition. Statistics
calculated by an unpaired t-test; * indicates p<0.05 versus sham. (H) Cytokine protein
levels in epididymal fat two weeks after scaffold implant measured by ELISA. Data
normalized to naïve fat. n=4-6 mice per condition.
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increased cellularity caused by scaffold implant is responsible for the three-fold
increase in Glut1 (Fig. 2.4B) and the increased glucose uptake measured in
epididymal fat implanted with scaffolds (Fig. 2.3A and 2.3B). Taken together, the
data indicates that scaffold implant results in tissue remodeling that is localized to
the implant site and characterized by the influx of many cells types that express
Glut1.
A logical concern with the level of immune infiltration seen after scaffold
implant is there could be an increase in pro-inflammatory mediators that would
lead to chronic low grade inflammation seen in mouse models and human patients
with obesity58–60. We are not concerned by this because we found that scaffold
implant appears to decrease TNF-a levels below those found in naïve fat and does
not increase IL-6 at the 14-day time point (Fig. 2.6H). These findings are congruent
with a recent publication demonstrating that PLG scaffold implant into the
epididymal fat decreases IL-6 and TNF-a61.
Enrichment of scaffold-recruited macrophages at the implant site correlates with
increased IGF-1 expression.
Our subsequent studies focused on understanding the source of elevated
IGF-1 following scaffold implant (Fig. 2.5B). Recently, bone marrow derived
macrophages were identified as a major source of IGF-1 in adipose tissue62. In our
study, flow cytometry revealed that scaffold implant resulted in a threefold increase
in macrophages as identified by expression of F4/80 and CD11b. In contrast,
tissue from mice receiving sham surgery had similar macrophage content to naïve
controls, which indicates the surgery alone does not recruit macrophages to the
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Figure 2.7. The effect of resident tissue macrophage depletion on scaffold
induced IGF-1 and Glut1 expression. (A) Number of F4/80 cells isolated from naïve
epididymal fat and epididymal fat receiving sham surgery or scaffolds 14 days after
implant. Data analyzed using a one-way ANOVA with Tukey’s multiple comparisons
test. * indicates p<0.05 versus naïve, † indicates p<0.05 versus sham. n= 4-6 mice
per condition. (B) Number of F4/80 cells isolated from naïve epididymal fat and
epididymal fat 48 hours after intraperitoneal injection of clodronate liposomes. Data
analyzed using an unpaired t-test; * indicates p<0.05 compared to naïve controls. n=56 mice per condition. (C) Timeline of clodronate liposome injection and scaffold implant
study. (D) Number of F4/80 cells isolated from the epididymal fat of mice receiving a
clodronate liposome injection 48 hours prior to scaffold implant (Sc+CLD) and mice
that received scaffolds but no clodronate liposome injection (Sc). (E) IGF-1 protein in
epididymal fat of mice receiving a clodronate liposome injection 48 hours prior to
scaffold implant and mice that only received scaffolds measured by ELISA. (F)
Western blot for Glut1 in epididymal fat. (G) Quantification of band intensity. (D, E, G)
Data analyzed using an unpaired t-test; * indicates p<0.05 compared to scaffold
controls. n=3-5 mice per condition.
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epididymal fat (Fig. 2.7A). To investigate if scaffold-recruited macrophages were
the source of the elevated IGF-1, we utilized an intraperitoneal injection of
clodronate liposomes to remove resident macrophages from the epididymal
adipose tissue prior to scaffold implant. Flow cytometry confirmed that clodronate
liposomes were effective in removing 70% of the resident macrophages 48 hours
after a single intraperitoneal injection (Fig. 2.7B). Interestingly, 14 days after
scaffold implant macrophage numbers in the epididymal fat were similar between
the untreated and chlodronate-treated groups (Fig. 2.7D); however, there was a
significant increase in IGF-1 in the epididymal fat of the chlodronate treated group
(Fig. 2.7E). Since 70% of resident macrophages are removed with clodronate
liposomes prior to scaffold implant (Fig. 2.7B), we conclude that 14 days after
scaffold implant there is a higher number of scaffold-recruited macrophages in the
epididymal fat of clodronate treated mice compared to controls. The data suggest
that scaffold-recruited macrophages are responsible, at least in part, for the
elevated IGF-1 detected 14 days after scaffold implant. We also investigated if
clodronate liposome administration had an effect on Glut1 levels in the epididymal
fat (Fig. 2.7F-G); however, Glut1 was unchanged.
PLG scaffolds decrease adiposity and improve glucose tolerance of mice fed a
high fat diet.
In lean mice, scaffolds decreased epididymal fat pad weight (Fig. 2.6G)
while increasing the tissue’s expression of Glut1 and IGF-1 (Fig. 2.4B and 2.4B).
These effects correlated with decreased fasting blood glucose levels (Fig. 2.2.1A)
and elevated basal glucose uptake at the implant site (Fig. 2.3B). These
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Figure 2.8. Body composition and glucose tolerance of high fat diet fed mice
two weeks after scaffold implant. (A) Timeline of the study. (B) Total body weight.
(C) Total body fat. (D) Weight of epididymal (eWAT), inguinal (iWAT) and subscapular
(sWAT) white adipose tissue. (E) Fasting blood glucose levels. (F) Intraperitoneal
glucose tolerance test and (G) area under the curves. Statistics calculated by one-way
ANOVA with a Tukey’s multiple comparisons test. * indicates p<0.05 compared to
HFD, † indicates p<0.05 compared to HFD+Sh. n=8-13 mice per group. HFD = high
fat diet, Sh = sham, Sc = scaffold, IPGTT = intraperitoneal glucose tolerance test, AUC
= area under the curve.
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findings led us to investigate if scaffolds could treat diet induced obesity and its
associated prediabetic state. We utilized a common mouse model in which male
C57BL/6 mice are fed a diet that is 60% fat. After one-week of the diet, total body
fat doubled (Sup. Fig. 2.11A) and the mice exhibited glucose intolerance (a
hallmark of prediabetes) characterized by elevated fasting blood glucose (Sup. Fig.
2.11C) and increased area under the curve during an intraperitoneal glucose

Figure 2.9. IGF-1 and Glut1 in the epididymal fat of high fat diet fed mice two
weeks after scaffold implant. (A) IGF-1 protein levels measured by ELISA. Data
normalized to chow. (B) Western blot assessing Glut1 levels. (C) Quantification of band
intensity. Data analyzed using a one-way ANOVA with a Tukey’s multiple comparisons
test. * indicates p<0.05 versus HFD, † indicates p<0.05 versus HFD+Sh. n=3-5 mice
per group. HFD = high fat diet, Sh = sham, Sc = scaffold.

tolerance test (Sup. Fig. 2.11E). It was at this timepoint that we administered the
scaffold-based intervention while keeping the mice on the high fat diet. One week
following scaffold implant therapeutic effects seemed apparent but were not
significant (Sup. Fig. 2.12). Two weeks after scaffold implant mice exhibited a trend
of decreased total body fat (Fig. 2.8C). By weighing individual fat pads, we found
that this trend was due in part to significant decreases in epididymal and inguinal
fat pad weight (Fig. 2.8D). While there was a trend of decreased fasting blood
glucose (Fig. 2.8E), glucose tolerance was significantly improved after two weeks
of scaffold implant as indicated by an intraperitoneal glucose tolerance test (Fig.
2.8F-G). We next measured IGF-1 and Glut1 in the epididymal fat of high fat diet
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fed mice two weeks after scaffold implant. We found that scaffold implant rescues
a decrease in epididymal IGF-1 expression caused by the high fat diet (Fig. 2.8A)
and increases Glut1 protein two-fold compared to mice on a high fat diet (Fig. 2.9BC). Taken together, these data demonstrate that PLG scaffold implant into the
epididymal fat decreases fat pad size and improves glucose tolerance in mice
challenged with a high fat diet and suggests that these effects are mediated by
elevated IGF-1 and Glut1 at the implant site.
2.4

Discussion.
The overarching goal for this research is to develop tissue engineering

platforms to correct adipose tissue dysfunction that underlies metabolic disease,
such as impaired glucose uptake. In these studies, we discovered that porous PLG
scaffolds decreased fasting blood glucose of healthy mice when implanted into the
epididymal fat. Interestingly, the relative decrease in fasting blood glucose we
attained is similar to that achieved after 3.5 weeks of treadmill training63. When
assessing fasting glucose uptake through the injection of a fluorescent glucose
tracer, we found the area in close proximity to the scaffold exhibited intense
glucose uptake. This area localizes with cellular components of the host response
observed in histological sections of the implant site. The localized increase in
glucose uptake is striking and demonstrates that cells attracted by the scaffold
have a substantial appetite for glucose, specifically when activated, such as during
the tissue remolding that follows biomaterial implant53,64,65. Considering all the
data, we propose that the mechanism of decreased blood glucose in response to
PLG scaffolds is as follows. Scaffold implant into the fat results in a new
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microenvironment that consists of blood vessels, extracellular matrix, fibroblasts,
mononuclear immune cells, and multinucleated giant cells. Within this
environment, cells degrade the scaffold into smaller pieces that are either removed
from or integrated with the surrounding tissue. This environment requires high
amounts of glucose relative to native fat and its glucose requirements can cause
blood glucose levels to decrease in the fasted state.
These findings raise an important question: Are the glucose lowering effects
specific to PLG or can other materials cause this effect? As outlined above, we
theorize the glucose lowering effect stems from the scaffold’s ability to induce and
support cellular activity associated with the host response. Synthetic materials,
such as PLG, support these cell-material interactions through protein
adsorption66,67. One factor that greatly influences protein absorption is
hydrophobicity68, thus we hypothesize that biomaterials with similar hydrophobic
properties to PLG would result in similar amounts of protein absorption, leading to
host responses that can lower blood glucose. In support of this hypothesis,
scaffolds made of polycaprolactone, a polymer with comparable hydrophobicity to
PLG, induce immune responses comparable to PLG scaffolds when implanted into
the epididymal fat31,69–71; however, it is currently unknown if polycaprolactone
scaffolds decrease blood glucose levels in mice. On the other hand, it is possible
that the glucose lowering effect is specific to PLG because its degradation products
are responsible. In support of this notion, lactate, which is released as PLG
degrades, modulates cellular metabolism72,73. Especially relevant to the current
work are reports that lactate increases expression of Glut1 in adipocytes74 and
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inhibits macrophage inflammatory activity75. Thus, it is possible that the therapeutic
effects of PLG scaffolds are linked to lactate release and tuning PLG properties to
increase lactate release rate76 would enhance the scaffold’s ability to modulate
blood glucose levels.
Currently, it is unclear if the scaffold’s effect on blood glucose levels is
permanent; however, we suspect that the effect is transient. We think that as the
host response resolves and pieces of the scaffold are either removed or integrated
with the surrounding tissue, cellular activity will diminish and so will the local
glucose utilization at the scaffold implant site. Following this reasoning, there will
be a point in time where glucose utilization gets low enough that blood glucose
levels increase to normal, “naïve” levels. It is unclear when exactly blood glucose
levels will return to normal, but the data in Figure 2.5B indicates that IGF-1
expression at 4 weeks is significantly lower than IGF-1 expression at 1 and 2
weeks. This suggests that the host response is resolving at 4 weeks and that blood
glucose levels may return to normal around that time. We hypothesize that by
engineering the scaffold to extend or augment cellular activities within the implant
site (e.g. drug delivery, modulating the implant’s size, surface area, surface
chemistry, degradation kinetics) the timeframe of lowered blood glucose could be
extended. Indeed, augmenting the scaffold’s effect on glucose uptake is an active
area of our research.
When investigating protein expression in epididymal fat with scaffolds, we
found substantial increases in Glut1 (three-fold) and IGF-1 (two-fold) compared to
control tissue. While the exact cellular source of Glut1 is unclear (this glucose
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transporter is ubiquitously expressed46), scaffold-recruited macrophages appear
to be the cause of elevated IGF-1 levels. Our conclusion is supported by recent
findings that macrophages produce high levels of IGF-1 and are a source of IGF1 in adipose tissue62,77. Increasing Glut1 and IGF-1 expression in the fat is exciting
from the point of view of treating both prediabetes as well as diabetes. For
example, Glut1 does not require insulin or any other hormone to participate in
glucose uptake48,78. In contrast, Glut4, the principal glucose transporter in muscle
and fat, requires insulin signaling for its translocation from intracellular stores to
the cell surface before it is functional79. Thus, if the tissue is insulin resistant or if
the patient is suffering from beta-cell failure associated with either type 1 or type 2
of diabetes, elevating Glut4 expression is likely futile, but targeting Glut1 is a viable
option. In support of this strategy, mice that overexpress Glut1 in their skeletal
muscle exhibit a 30% decrease in fasting blood glucose levels and enhanced
glucose uptake in their muscle that does not require insulin44. Regarding IGF-1, its
receptor is homologous to the insulin receptor and shares many overlapping
downstream signaling pathways. IGF-1 binding to its receptor (IGF-1R) results in
Glut4 translocation and glucose uptake80,81; however, IGF-1 can also bind the
insulin receptor, albeit with lower affinity than insulin, and promote glucose
uptake82. Since the scaffold induces high levels of IGF-1 locally, this may cause
glucose uptake in an insulin resistant tissue that requires high levels of receptor
activation, or in a patient that is suffering from beta cell failure and no insulin is
available. Taken together, PLG scaffolds deliver a “one-two punch” in treating
glucose intolerance in tissues: (i) inducing expression of a glucose transporter that
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does not require insulin and (ii) inducing high local levels of a molecule that acts
like insulin.
In terms of therapeutic applications, scaffolds implanted into the epididymal
fat improved glucose tolerance in mice fed a high fat diet. In this model, glucose
intolerance develops within 3 days83,84. The excessive intake of dietary fat causes
rapid expansion of the epididymal adipose tissue, which becomes insulin resistant
due to high levels of fatty acids in the tissue. The insulin resistance in the
epididymal fat contributes to the glucose intolerant state83. The improvement in
glucose tolerance in this study correlated with elevations in Glut1 and IGF-1
suggesting that increased glucose uptake at the implant site played a role. High
fat diet fed mice treated with scaffolds also had smaller epididymal fat pads, which
agrees with our experiments in lean mice that showed scaffold implant decreased
adipocyte cell size and epidydimal fat pad weight; the data indicate that the host
response to the scaffold in the fat was responsible. We think that scaffolds
decrease fat pad size because the cellular activity invoked to degrade and
integrate it with fat pad utilizes not only glucose, but also fatty acids, which are
provided by the surrounding adipocytes. As the tissue remodeling ensues, local fat
stores are depleted, and the fat pad decreases in size. This explanation is
supported by a large body of research indicating that cellular activity associated
with wound healing is largely fueled by fatty acid metabolism85,86. Taken together,
these findings demonstrate increased cellular activity in the adipose tissue caused
by the scaffold is beneficial to mice fed the high fat diet because it mitigates the
high levels of fatty acids and glucose that lead to the obese, prediabetic state.
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This work indicates that the host response to PLG scaffolds protects mice
from diet induced obesity and glucose intolerance. These results were unexpected,
and somewhat ironic, since the biomaterials field has focused heavily on mitigating
or preventing the host response to biomaterial implant because of its detrimental
effects in some tissue engineering applications32,87. To our knowledge, we are the
first to report a systemic metabolic effect (beneficial or otherwise) due to
biomaterial implant. As is indicated by many extensive, highly cited, and even
recent reviews66,67,88, the field has focused on the host response to biomaterials in
the implanted tissue while the impact on distant tissues or systemic responses
have been understudied or undetected. Our work raises the possibility that, in
addition to PLG scaffolds, there are other tissue engineering constructs or
implantable devices already in use that modulate physiology distant from the
implant site. The organs of the body function in concert, and tissues commonly
addressed by tissue engineers (e.g. bone and muscle) modulate each other’s
physiology through endocrine signaling89. Thus, while it is paramount that novel
and repurposed biomaterials for implantation do not negatively impact the local
tissue, the field would be amiss if future studies did not address how tissueengineered environments can be leveraged to modulate physiology or pathology
in distant organs.
In conclusion, PLG scaffolds increase glucose uptake in the epididymal fat
and decrease fasting blood glucose in healthy mice. Glut1 and IGF-1, which
mediate glucose uptake, are elevated in the fat tissue after scaffold implant.
Histological analysis of the implant site indicates increased cellularity in the
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immediate vicinity of the scaffold and suggests several cell types involved in the
host response are responsible for elevated Glut1 levels. Enrichment of scaffoldrecruited macrophages at the implant site correlated with increased IGF-1 levels,
suggesting these macrophages are responsible for elevated IGF-1. The data
indicate that the host response to a PLG scaffold imparts a metabolic load on the
mouse that is sufficient to decrease systemic blood glucose levels, which is
remarkable. Regarding therapeutic application, treatment with PLG scaffolds
decreases adiposity and improves glucose tolerance in mice fed a high fat diet,
indicating the increased cellular activity in the adipose tissue invoked by scaffold
implant is protective against the overnutrition that makes the mouse obese and
prediabetic. Thus, we conclude PLG scaffolds are a promising platform for treating
metabolic disease since the polymer alone has beneficial effects and these
devices are readily engineered for drug or cell delivery that may enhance their
efficacy. More broadly, this work reaffirms that in addition to the local tissue
responses induced by biomaterial implant, which are usually the focus of the field,
there are systemic effects that may be leveraged for therapy. Finally, we
hypothesize that further unraveling how the host response to PLG mitigates the
metabolic complications of diet induced obesity will identify new drug targets and
avenues for therapy.
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2.5

Supplemental Results.

Immune Cell Gating Scheme
Gating CD45+ cells

Removing debris

Removing aggregate
cells

Removing Ly6G cells
(neutrophils)

Naive

CLD 48 hours

Scaff 14 days

Figure 2.10. Flow Cytometry Gating Strategy. Gating scheme and representative
F4/80 versus CD11b plots used to identify macrophages in naïve adipose tissue,
adipose tissue 48 hours after clodronate injections, and adipose tissue 14 days after
implant of PLG scaffolds.
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Figure 2.11. Body composition and glucose tolerance in C57BL/6 mice one week
after HFD feeding. (A) Fat mass and (B) lean mass from DEXA scans of mice kept on
a chow diet and mice kept on a 60% high fat diet for one week. (C) Fasting blood
glucose. (D) Intraperitoneal glucose tolerance test conducted one week after starting
mice on the HFD. (E) Area under the curve. Statistics calculated using an Unpaired Ttest * represents p<0.05 versus chow. n=10 for chow mice; n=30 for HFD mice.
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Figure 2.12. Effect of scaffolds on body composition and glucose tolerance of
mice fed a high fat diet one week after scaffold implant. (A) Timeline of the study.
(B) Body weight. (C) Total body fat measured by DEXA scans. (D) Fasting blood
glucose measurements made 1 week after scaffold implant. (E) Intraperitoneal glucose
tolerance test and (F) area under the curve completed 1 week after scaffold implant.
Statistics calculated by one-way ANOVA with a Tukey’s multiple comparisons test. *
represents p<0.05 compared to HFD control, † represents p<0.05 compared to
HFD+Sh. For all conditions n=5 mice per condition. HFD = high fat diet, Sh = sham,
and Sc = scaffold.
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CHAPTER 3
RESVERATROL DELIVERY FROM SCAFFOLDS TO THE
EPIDIDYMAL ADIPOSE TISSUE DECREASES TOTAL BODY FAT
AND IMPROVES GLUCOSE TOLERANCE IN MICE CHALLENGED
WITH A HIGH FAT DIET
3.1

Introduction.
Obesity is a major burden on the United States healthcare system with over

two thirds of the adult population classified as overweight and over one third as
obese90. Adding to this burden is obesity’s association with type 2 diabetes,
cardiovascular disease and certain types of cancer4. With respect to type 2
diabetes, this link is undeniable; nearly 90% of those suffering from type 2 diabetes
are overweight or obese10.
There is no question that adipose tissue dysfunction constitutes a
mechanistic link between the obese and diabetic disease states6. Healthy adipose
tissue functions as an energy reservoir which stores lipids in times of caloric
surplus and releases lipids in times of caloric deficit. However, the adipose tissue
has a limited storage capacity, and excess lipid buildup that occurs during obesity
leads to dysregulation of adipocytes, the most prevalent cells within the tissue12.
Lipid accumulation is particularly troublesome in adipose tissue around internal
organs (visceral fat)12. The excess lipid in visceral fat causes inflammation, which
leads to the influx of inflammatory macrophages. Inflamed visceral fat then
secretes large amounts of lipids into the bloodstream resulting in lipid build up in
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peripheral tissues, such as the skeletal muscle and liver, causing insulin resistance
in those tissues16. Eventually, insulin resistance throughout the body causes a
state of glucose intolerance leading to hyperglycemia. Chronic hyperglycemia
damages vital organs, including the pancreas, whose failure marks the onset of
type 2 diabetes.
The critical role of lipid accumulation in adipose tissue, in particular the
visceral adipose tissue, in the development of glucose intolerance suggests
treatment strategies focused on engineering visceral adipose tissue lipid utilization
could represent a promising strategy for obese patients who are developing
diabetes. Currently, the standard of care for obese diabetics, in combination with
diet and exercise, is anti-diabetic medications that improve insulin sensitivity
and/or promote insulin production. However, these medications fail to address the
underlying adipose dysfunction and, in addition, have side effects that hinder their
safety, patient compliance, and effectiveness20.
Our lab is currently investigating the use of polymer scaffold implants to
engineer the fat’s lipid metabolism in the visceral adipose tissue as a therapeutic
strategy to treat obesity and its related disorders. In a previous study we
discovered that the implant of scaffolds made of poly(lactide-co-glycolide) (PLG)
containing no drug payload, decreased the epididymal adipose tissue (visceral
adipose tissue of the mouse) weight in both healthy mice and mice challenged with
a high fat diet, suggesting elevated metabolism of lipid stores91. These observed
effects were attributed to the cellular remodeling in the adipose tissue caused by
the host response to the polymer.
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To further investigate the therapeutic effects of these scaffolds as well as
investigate ways to augment this lipid burning effect, we encapsulated resveratrol
(trans-3,5,4’-trihydroxystilbene), a naturally occurring polyphenol that has been
shown to mimic the effects of caloric restriction92–94 within the matrix of our PLG
scaffolds. Specifically, resveratrol has been shown to adipocyte lipid utilization by
increasing expression of carnitine palmitoyltransferase 1 (CPT1)34, the rate limiting
enzyme involved in fatty acid oxidation. This effect and others have been linked to
decreased obesity and improved glucose tolerance in rodents and primates fed a
high fat diet while treated with oral administration of resveratrol92,95. However,
therapeutic efficacy requires high daily doses of resveratrol (30-400 mg/kg/day) in
order to overcome resveratrol’s rapid first pass metabolism, which hinders its
bioactivity35,96. However, delivery of resveratrol directly to the adipose tissue from
polymer scaffolds could compensate for the molecule’s bioavailability issues and
allow for extended therapeutic effects with minimal dosing.
To test this hypothesis, we implanted resveratrol loaded PLG scaffolds into
the epididymal adipose tissue and assessed the ability to reduce fat accumulation
and improve glucose tolerance in a mouse model of diet induced obesity. In this
mouse model, C57BL/6 mice are fed a diet containing high fat content and rapidly
gain fat mass and become insulin resistant due to lipid accumulation in peripheral
tissues after just one week83. Therefore, in order to test the ability of scaffolds to
mitigate this lipid accumulation, we surgically implanted these scaffolds into the
adipose tissue after one week of high fat diet feeding. Interestingly, resveratrol
loaded scaffolds were able to reduce lipid accumulation and improve glucose
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tolerance in high fat diet fed mice, however scaffolds containing no drug payload
also had noticeable effects on these parameters.
3.2

Methods.

Particle Fabrication.
Particles were produced by an oil-in-water emulsion-solvent evaporation
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma)
and ethanol (Sigma) containing 6% w/v PLG (purchased from Evonik, 75:25 mol
ratio lactide to glycolide, 0.76 dL/g) and 10mg/mL of trans-resveratrol (Sigma
R5010). The aqueous phase consisted of 1% w/v poly(vinyl alcohol) (Sigma)
dissolved in ultrapure water. The oil phase was homogenized with the aqueous
phase using a 1:7 volume ratio with a benchtop homogenizer. The emulsion was
then immediately added to ultrapure water and stirred for 5 hours to allow particles
to harden and organic solvents to evaporate. Particles were collected via
centrifugation, washed with ultrapure water, and lyophilized.
Scaffold Fabrication.
Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl
particles in a 1:30 ratio and the mixture was then pelleted in a die. Scaffolds were
gas-foamed using 800 psi CO2 at room temperature in a pressure vessel. The salt
porogen was removed by washing in ultrapure water. Complete salt removal was
confirmed by scaffold weight and microscopy. Scaffolds that did not contain
resveratrol were fabricated from particles produced using an oil phase that did not
contain resveratrol or ethanol. From here on resveratrol loaded scaffolds are
referred to as “resveratrol scaffolds” and scaffolds that do not contain resveratrol
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are referred to as “blank scaffolds”.
Quantification of Resveratrol within Scaffolds.
Resveratrol scaffolds were dissolved in dimethyl sulfoxide (DMSO) and
samples were loaded into a UV-Starâ 96 well plate (Greiner Bio-One) and
scanned for absorption at 330 nm using a Biotek Synergy 2 plate reader.
Resveratrol content was determined with an 8-point standard curve produced by
making ½ dilutions of a 1 mg/mL resveratrol solution in DMSO. All resveratrol
standards contained PLG at the same concentration as the scaffold samples.
Animal Studies.
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks
of age. All animals were housed with ad libitum access to water and food in a
temperature-controlled room with a 12:12 h light:dark cycle. All procedures were
performed in accordance with NIH Guidelines for Care and Use of Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of South Carolina. Mice were allowed to acclimate for two weeks prior
to study.
High Fat Diet Feeding.
After two weeks of acclimation, mice were placed on a 60% high-fat diet
(Research Diets D12492) while a control group was kept on a normal diet (Teklad
8904). On a caloric basis, the high-fat diet consisted of 60% fat from lard, 20%
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet
contained 12% fat, 66%carbohydrate, and 22% protein (total 3.0 kcal/g). Mice were
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kept on the high fat diet for one week prior to scaffold implantation and remained
on the diet for the remainder of the experiment.
Scaffold Implantation.
Mice received scaffold implants into the epididymal fat as previously
described31. Briefly, mice were anesthetized with a 2% mixture of isoflurane and
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile
fashion. Following a lower abdominal midline incision, each epididymal fat
pad and wrapped around the scaffolds so that the scaffolds were in the center of
the tissue. The abdominal wall was then closed with a running stitch, and the skin
was closed with wound clips. All mice received two scaffolds per fat pad (i.e. each
mouse received 4 scaffolds).
Duel Energy X-Ray Absorptiometry (DEXA).
Body composition was assessed using DEXA scans (Lunar PIXImus). Each
mouse was anesthetized for the duration of the procedure (5 min) by exposure to
2% isoflurane-oxygen gas via a nose cone. Each mouse was placed on the
scanner bed in the prone position, with the limbs and tail stretched away from the
body. One scan per mouse was performed and analyzed with PIXImus software
(Lunar). The head was excluded from calculation using a manual ROI. The
PIXImus was calibrated with an aluminum/Lucite phantom (corresponding to bone
mineral density = 0.0592 g/cm2 and 12.5% fat) on each day of testing according
the manufacturer’s instructions.
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Intraperitoneal Glucose Tolerance Test.
Mice were fasted for 6-hours before receiving injections of D-glucose into
the intraperitoneal cavity. Glucose administered was normalized to the lean mass
calculated via a DEXA scan that was conducted one-day prior (2g glucose per kg
lean mass). Blood samples were collected via a tail vein prick at 0, 15, 30, 60, 90,
and 120 minutes after glucose administration. Glucose measurements were
obtained using a handheld glucose meter (Accu-Chek Nano, SmartView).
Food Intake Measurements.
Food was weighed at the beginning and end of each week and the total
grams of food consumed was calculated. To obtain kcal per mouse, weight of food
consumed was normalized by the number of mice in the cage and multiplied by
the calorie density in the food (5.24 kcal/gram).
Enzyme Linked Immunosorbent Assay.
Blood was collected from mice fasted for 6 hours retro-orbitally into EDTA
coated tubes, spun down at 10,000 g, and plasma was isolated. Insulin ELISA kit
was purchased from ALPCO. The assay was performed according to the
manufacturer’s instructions.
Western Blotting.
Tissue samples were homogenized in RIPA buffer (Thermo Scientific)
supplemented with protease inhibitor cocktail (Thermo Scientific), phospho-stop
(Roche), and phenylmethane sulfonyl fluoride (Sigma). Following homogenization,
protein was isolated via centrifugation at 18,000 g for 45 minutes. Protein
concentrations were determined using a BCA assay (Thermo Scientific). Lysates
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(30 ug adipose tissue, 100 ug gastrocnemius and liver) were separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred
to a nitrocellulose membrane (GE Healthcare Life Sciences) and incubated with
appropriate antibodies. Secondary antibody was a horseradish peroxidase (HRP)conjugated antirabbit immunoglobulin G (IgG) grown in goat (Abcam). Proteins
were visualized using SuperSignal West Pico substrate (Thermo Scientific).
Antibodies to total Akt, phospho-Akt ser 473, and GAPDH were purchased from
Cell Signaling Technology (1:1000 dilution). The antibody for Glut4 was purchased
from Sigma Aldrich (1:1000 dilution). The antibody for CPT1A was purchased from
Abcam (1:1000 dilution).
Resveratrol Extraction from Epididymal Fat Pads.
Resveratrol was extracted from epididymal fat pads using a technique
derived from the work of Juan et al. Each fat pad was added to 2 mL of an acidified
methanol solution consisting of 80% methanol (v/v), 17.5% ultrapure water, 2.5%
acetic acid and 10µL of 15% (v/v) ascorbic acid. Fad pads were minced finely with
scissors and homogenized using a Polytron tissue homogenizer (Kinematica). The
homogenizer was cleaned twice with 1mL of the acidified methanol solution
resulting in a final volume of 4mL per tissue. Following homogenization, samples
were vortexed for 5 minutes and centrifuged at 3,000 g for 30 minutes at 4°C. The
supernatant was transferred to a clean tube and the solid residue was treated 2
more times with the procedure outlined above. The supernatant was then reduced
to a final volume of ~1mL with a rotary evaporator, passed through a 3 kDa
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molecular weight cutoff filter, and stored in an amber vial at -20 oC prior to HPLC
analysis.
A Thermo Ultimate 3000 binary gradient system was used for HPLC
analysis. The column used was a Chromegabond WR C18 and the flow rate was
kept at 0.2 mL/min. The UV detector was Agilent G1315B Diode Array Detector
set for 306nm. Solvent A was water and Solvent B was Acetonitrile. From 0-30min
solvent was 90% A and 10% B. From 30min to 31 min solvent was 5% A and 95%
B. From 31min on solvent was 90% A and 10% B. A fresh stock of trans-resveratrol
was used to determine the correct elution time. HPLC/UV-Vis was used to detect
resveratrol in the stock solution and the samples extracted from epididymal fat.
Statistical Analysis.
Data is presented as mean ± standard error of the mean. All statistical
analyses were conducted using Prism software version 8 (GraphPad). Data sets
comparing three or more groups were analyzed using a one-way ANOVA with
Tukey’s multiple comparisons test. Data sets comparing two or more groups over
time were analyzed using a two-way ANOVA with Tukey’s multiple comparisons
test. P values less than 0.05 were considered significant.
3.3

Results.

Characterization of scaffolds.
Representative SEM images of a scaffold are presented in Figure 3.1.
Scaffold size and structure was unaffected by encapsulating resveratrol into the
polymer matrix. Scaffolds were 5 mm in diameter and 2 mm in height with an
average pore size of 370 ± 58 µm. Drug loading was 44.7 ± 3.2 µg of resveratrol
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Figure 3.1. Images of a typical scaffold. Scanning electron microscope images of a
scaffold. (A) Top profile. (B) Cross sectional profile. Scale bar is 1mm.

per mg of polymer. Blank and resveratrol scaffolds had similar weights (Table 3.1);
thus, the only difference between the two types of scaffolds was resveratrol
content.
Table 3.1. Resveratrol loading and scaffold weights.

Impact of scaffolds on mice challenged with a high fat diet.
Daily oral delivery of resveratrol protects mice from high fat diet induced
obesity and glucose intolerance. We hypothesized we could protect mice from a
high fat diet with a single administration of resveratrol delivered over time through
a scaffold implanted into the epididymal fat. The experimental timeline is depicted
in Figure 3.2A. After one week of high fat diet, we implanted the scaffolds and then
continued the mice on the diet for an additional five weeks. Each mouse received
two scaffolds per fat pad. The resveratrol dose was calculated to be 272
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Figure 3.2. Effect of scaffolds on body composition in high fat diet fed mice. (A)
Timeline of the study. (B) Percent change in body weight relative to the day of scaffold
implant. (C) Percent change in fat mass relative to the day of scaffold implant. (D)
Weekly kcal intake per mouse over the 5-week experiment. For body weight and
composition, statistics were calculated by two-way ANOVA with a Tukey’s multiple
comparisons test. For food consumption, statistics were calculated by one-way ANOVA
with a Tukey’s multiple comparisons test. * p<0.05 versus HFD+Sh. For all conditions
and timepoints n=4-5 mice. ND = normal diet; HFD = high fat diet; Sh = sham surgery;
Sc = blank scaffold; Rsv = resveratrol scaffold.

± 21 µg or ~14 mg/kg. Five weeks after scaffold implant, mice with scaffolds,
regardless of resveratrol content, gained significantly less weight than the control
mice that received the scaffold implant procedure, but no scaffold, which are
referred to as “sham” from this point on (Figure 3.2B). Body composition analysis
using DEXA indicated that mice with resveratrol scaffolds gained significantly less
body fat compared to sham mice. The mice with blank scaffolds showed trends of
lower body fat, but statistical significance (p<0.05) was not achieved (Figure 3.2C).
These effects occurred without significant changes in food consumption between

50

the high fat diet fed groups (Figure 3.2D). Taken together, the data indicate that
resveratrol scaffolds decrease fat mass accumulation caused by the high fat diet
and achieves this effect through means other than decreasing food intake.
In this mouse model of diet induced obesity, reductions in weight gain,
specifically fat mass, often correlate with improved insulin sensitivity and glucose
tolerance. Mice that received scaffolds, regardless of resveratrol content, had
lower fasting insulin levels, but identical fasting glucose levels compared to the

Figure 3.3. Fasting insulin and glucose levels and glucose tolerance 5 weeks
after scaffold delivery in high fat diet fed mice. (A) Fasting insulin measured in
plasma by ELISA. (B) Fasting glucose measured in whole blood by glucometer. (C)
Absolute blood glucose versus time during an intraperitoneal glucose tolerance test
and (D) area under the curve. Statistics were calculated by one-way ANOVA with a
Tukey’s multiple comparisons test. *p<0.05 versus HFD+Sh. n=4-5 mice per group.

sham mice, indicating whole-body insulin sensitivity was improved in mice with
scaffolds (Figure 3.3A-B). However, an intraperitoneal glucose tolerance test
revealed that only the resveratrol group had a greater ability to clear a load of
glucose from the bloodstream compared to the sham group (Figure 3.3C-D).
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Taken together, the data indicate that under fasting conditions, scaffolds are
sufficient to improve insulin’s control of blood glucose levels; in contrast, when
challenged with a bolus of glucose, resveratrol scaffolds are required to improve
glucose clearance from the bloodstream.
The effect of scaffolds on CPT1 expression in the epididymal fat.
The observed reduction in total body fat paired with no changes in caloric
intake led us to investigate the effect of scaffolds on epididymal fat pad size and
protein levels of carnitine palmitoyltransferase 1 (CPT1), the rate limiting enzyme
in fatty acid oxidation. The hypothesis being that decreases in epididymal fat

Figure 3.4. Effect of scaffolds on CPT1 in the epididymal fat. Epididymal fat pad
weights, representative western blots, and band quantification for carnitine
palmitoyltransferase 1 (CPT1) in the epididymal fat (A-C) five weeks and (D-F) two
weeks after implant. Statistics were calculated by one-way ANOVA with a Tukey’s
multiple comparisons test. * represents p<0.05 compared to HFD+Sh, † represents
p<0.05 compared to HFD+Sc. n=4-5 mice per group.
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contributed to overall decreases in total body fat and that decreases in epididymal
fat were due to elevated levels of fatty acid utilization, for which CPT1 is an
accepted marker. Five weeks after scaffold implant, we did not detect any
differences between epididymal fat pad size or levels of CPT1 among the high fat
diet fed groups (Figure 3.4A-C); therefore, in a separate cohort of animals,
following the exact experimental design depicted in Figure 2a, we conducted these
measurements two weeks after scaffold delivery. At this time point, we did not
detect significant differences between epididymal fat pad weight between the high
fat diet fed groups, although the resveratrol group exhibited a trend of decrease
(Figure 3.4D); however, CPT1 protein was significantly higher in the epididymal fat
of the resveratrol scaffold group compared to the blank scaffold group and the
sham control (Figure 3.4E-F). Additionally, mice receiving blank scaffolds showed
significant elevations in CPT1 in the epididymal fat compared to sham controls,
suggesting scaffolds alone also elevate fatty acid oxidation. Taken together, the
data indicate that blank scaffolds increase levels of CPT1 in the epididymal fat 2
weeks after implant and this effect is augmented by resveratrol delivery.
Furthermore, the data suggest that increases in fatty acid oxidation in the
epididymal fat contributes to the decreased levels of total body fat we measured
via DEXA 5 weeks after scaffold administration (Figure 3.2C).
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Figure 3.5. Assessment of cellular infiltration and CPT1 expression within
scaffold implants. Representative images of epididymal adipose tissue sections from
high fat diet fed mice receiving a sham surgery, blank scaffold implant, or resveratrol
scaffold implant. Sections are from two weeks after surgery/implant. (A-F) Hematoxylin
and eosin staining. (G-L) Immunohistochemistry staining for CPT1. Scale bars
represent 500µm for 4x images and 50µm for 40x images.
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Distribution of CPT1 expression within the epididymal fat.
In order to better understand the cellular changes occurring within the
epididymal fat that lead to elevated CPT1 expression at the two-week time point,
tissue sections from mice on the two-week high fat diet study were evaluated using
hematoxylin and eosin staining. Large amounts of cellular infiltration were
observed in mice receiving blank and resveratrol scaffolds relative to mice
receiving the sham surgery (Figure 3.5A-C). Inspection at higher magnification
showed an overall similar response to both scaffold types, however the epididymal
adipose tissue from receiving resveratrol scaffolds showed trends of higher eosin
staining, suggesting the possibility of greater extracellular matrix deposition
(Figure 3.5D-F). Immunohistochemistry staining was then used to better visualize
cells highly expressing CPT1. Interestingly, CPT1 was seen expressed highest in
cells recruited to the epididymal adipose tissue by both scaffold types (Figure
3.5G-I). Further inspection of the implant site did not reveal any obvious
differences between cells expressing CPT1 in blank vs resveratrol scaffolds
(Figure 3.5J-L). However, it was noticed that the multinucleated giant cells which
could be found in adipose tissue from both scaffold types, expressed high levels
of CPT1.
Resveratrol content in epididymal fat two and five weeks after scaffold implant.
While the therapeutic effects of resveratrol delivery were apparent five
weeks after scaffold implant, it was unclear if resveratrol was still present in the
epididymal fat at that time point. To address this question, we measured
resveratrol in epididymal fat pads two and five weeks after scaffold implant using
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Figure 3.6. Resveratrol content in epididymal fat two and five weeks after
scaffold implant. (A) HPLC chromatograms depicting resveratrol content in
epididymal fat two and five weeks after implanting resveratrol scaffolds. For
comparison, epididymal fat pads that did not receive scaffolds but were homogenized
with either fresh resveratrol scaffolds (Sc+Rsv) or blank scaffolds (Sc) were included
for comparison. (B) Resveratrol content in the epididymal fat depicted as peak area
calculated from HPLC chromatograms. n = 3 mice per group.

HPLC (Week 2 and Week 5, respectively, Figure 3.6). For comparison, we also
analyzed epididymal fat pads that did not receive scaffolds in vivo but were
processed with either two fresh resveratrol scaffolds (Sc+Rsv, Figure 3.6) or two
fresh blank scaffolds (Sc, Figure 3.6). Two scaffolds were used because in the in
vivo study mice received two scaffolds per fat pad. HPLC indicated that resveratrol
was present within the epididymal fat at both two and five weeks after scaffold
implant, with approximately 2% of the initial resveratrol dose remaining at two
weeks and approximately 1% remaining at five weeks (Figure 3.6).
3.4

Discussion.
The overarching goal for the research is to develop bioengineering

strategies to treat metabolic disorders such as obesity and its associated insulin
resistant state. In this work, we engineered polymer scaffolds to release resveratrol
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following their implant into epididymal fat pads. Resveratrol delivery from the
scaffolds decreased total body fat and improved glucose tolerance fed a high fat
diet designed to induce fat gain and insulin resistance, which are two key goals for
treating obese diabetics, a patient population that is difficult to treat. Resveratrol is
a small molecule with anti-obesity and anti-diabetic properties notorious for its poor
bioavailability that requires large oral doses administered daily in order to realize
its therapeutic effects. For example, mice94,95,97,98, rats99–101, rhesus monkeys92
and humans93,102,103 require doses that range from 20-400 mg/kg/day to induce
weight loss, improve glucose tolerance, and/or decrease insulin resistance. In
stark contrast to these large and frequent doses, scaffolds achieved therapeutic
effects with a single administration and a resveratrol dose equivalent to 14 mg/kg.
Our results demonstrate the potential of biomaterial implants to address
bioavailability issues that hinder the therapeutic potential or translation of small
molecule drugs. Furthermore, while the beneficial effects of oral resveratrol
delivery on obesity and insulin resistance are established, ours is the first study
demonstrating that resveratrol delivery directly to the visceral adipose tissue can
induce similar effects with a substantially lower, single dose.
We found that blank scaffolds decreased total body weight, which was likely
due to decreased total body fat, although we did not have sufficient power to detect
significance. Interestingly, there was no change in epididymal fat pad weight
suggesting that fat accumulation was decreased elsewhere. Blank scaffolds also
decreased plasma insulin levels indicating that the mice were more insulin
sensitive compared to the sham control group. Taken together, these findings
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suggest that lipid accumulation in the lean tissue was decreased by blank scaffolds
because lipid accumulation in the skeletal muscle and liver are major drivers of
insulin resistance in high fat diet fed mice83.
If lipid accumulation was decreased in the lean tissue, what was the fate of
this lipid? We found that blank scaffolds increased CPT1 in the epididymal fat,
which is the rate limiting enzyme in fatty acid oxidation 104 and an accepted marker
for increased fatty acid utilization
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. Thus, we propose that scaffolds increased

lipid utilization in the epididymal fat, which led to decreased lipid accumulation in
lean tissues, lower body fat, and improved insulin sensitivity (as measured by
plasma insulin levels).
An important question is, why do scaffolds increase CPT1 expression in the
epididymal fat? Implanting scaffolds into the epididymal fat results in cellular
infiltration in the immediate vicinity of the scaffold (Figure 3.5). Many of these cells
are macrophages31,61 that express the anti-inflammatory markers CD206 and
Arginase 161. The CPT1 isoform we measured (CPT1A), is the isoform expressed
by macrophages64. Furthermore, when a biomaterial is too large to allow for
macrophage phagocytosis, multinucleated giant cells are formed via macrophage
fusion
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. Immunohistochemistry staining revealed the multinucleated cells that

from in the adipose tissue as a response to our biomaterial implants highly express
CPT1 (Figure 3.5). In addition, CD206 and arginase levels correlate with CPT1
levels in macrophages because they are all upregulated during alternative
activation107, which we have demonstrated occurs when these scaffolds are
implanted into epididymal fat61. Taken together, we hypothesize that the
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macrophages and multinucleated giant cells that accumulate in the adipose tissue
following scaffold implant are responsible for the elevated CPT1 levels and that
their activity within the implant site leads to decreased total body fat by elevating
the net utilization of fatty acids within the epididymal adipose tissue.
We also found that resveratrol scaffolds increased CPT1 to a greater
degree than blank scaffolds. While immunohistochemistry did not reveal any
obvious differences in CPT1 expression within the cellular infiltration seen in blank
and resveratrol scaffolds, resveratrol has been demonstrated to elevate CPT1
expression in adipocytes. In adipocytes, CPT1 expression is controlled through the
activation of PPARg, which resveratrol and its metabolites can bind and activate108.
Furthermore, resveratrol treatment increases CPT1 expression in cultured
adipocytes34,109. Based on these published studies, we propose that resveratrol
scaffolds may increase CPT1 levels in the adipocytes in the epididymal fat;
however, it is possible that resveratrol increases CPT1 levels in macrophages or
other stromal vascular cells that reside within the scaffold implant site as well and
these effects were unable to be seen using immunohistochemistry. To our
knowledge, the impact of resveratrol on CPT1 expression in non-adipocytes has
not been reported.
Considering all the data, we propose the following mechanism for the
scaffold’s therapeutic effects on mice fed a high fat diet. Scaffolds elevate CPT1
expression in the epididymal fat, which is further augmented by resveratrol. We
hypothesize that this increases fatty acid utilization locally and decreases fatty acid
accumulation throughout the mouse and, therefore, total body fat. Increased fatty
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acid utilization at the scaffold implant site and decreased fatty acid accumulation
in other tissues improves whole body insulin resistance reflected in the decreased
plasma insulin levels. Overall, scaffold implant into the epididymal fat and
resveratrol delivery exert exciting therapeutic effects on body composition, insulin
resistance, and glucose tolerance in mice fed a high fat diet.
HPLC indicated that resveratrol was still present in the epididymal fat at
both two and five weeks after scaffold implant, with approximately 2% of the initial
dose remaining at two weeks and approximately 1% remaining at five weeks.
These are not trivial amounts of drug. We delivered ~136 µg of resveratrol to a fat
pad. At 2 weeks the fat pads weighed 350 mg and at 5 weeks they weighed 1000
mg (Figure 3.4). Taking the density of fat to be 0.9 mg/mL 110, the concentration in
the tissue might have been 35 µM at 2 weeks and 5 µM at 5 weeks if the drug was
evenly distributed throughout the tissue. For comparison, resveratrol at 25 µM is
sufficient to induce CPT1 expression in cultured adipocytes 34. Moving forward with
our approach, an obvious improvement would be to decrease the rate of drug
release, which we hypothesize would increase the overall efficacy and the
therapeutic window of the resveratrol scaffold. We believe this could be
accomplished through decreasing the specific surface area of the scaffold for drug
delivery and work is currently underway developing the next generation of
scaffolds to control lipid utilization and storage in adipose tissue for the treatment
of obesity and other metabolic syndromes.
One drawback to this therapeutic approach is the invasiveness of the
implant procedure. The visceral adipose tissue is located within the abdominal
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cavity therefore a surgical procedure is required to place the scaffold in the tissue
of interest. However, visceral adipose tissue has been shown to have lower lipid
storage capacity than subcutaneous counterparts12 and thus require less lipid
accumulation to become dysregulated. Additionally, the secretion of inflammatory
cytokines from visceral adipose tissue has been linked to systemic inflammation in
obese humans111. While we believe that these reasons support the choice of the
visceral adipose tissue for these studies, future studies will be aimed at
investigating if these effects can be repeated in other fat pads in the body,
specifically subcutaneous fat pads such as the inguinal fat.
In conclusion, implanting poly(lactide-co-glycolide) scaffolds into the
epididymal fat decreases body weight in mice fed a high fat diet and body
composition analysis via DEXA suggests this effect is due to decreased total body
fat. Mice with scaffolds also had plasma insulin and blood glucose levels on par
with mice fed a chow diet indicating an improvement in whole body insulin
sensitivity. Engineering the scaffolds to release resveratrol led to a significant
reduction in total body fat and an enhanced ability to clear a bolus of glucose from
the blood stream during an intraperitoneal glucose tolerance test. While epididymal
fat pad weights were unchanged for either scaffold group, carnitine
palmitoyltransferase 1 (CPT1), the rate limiting enzyme in fatty acid oxidation, was
increased in the scaffold group and this expression was further enhanced by
resveratrol. Mechanistically, we propose that scaffolds increase fatty acid oxidation
in the epididymal fat, an effect that is enhanced by resveratrol, and this leads to
decreased lipid deposition in lean tissue throughout the mouse, decreasing total
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body fat and whole-body insulin resistance. Regarding the enhanced performance
of the resveratrol group during the glucose tolerance test, we propose that
resveratrol delivery to the epididymal fat enhanced its ability for glucose uptake
compared with fat that received blank scaffolds. Remarkably, the enhancements
in therapy with resveratrol are achieved with a single dose of 14 mg/kg, which is a
substantial improvement over daily oral doses in the range of 20-400 mg/kg
reported in the literature. Thus, we conclude that delivering resveratrol directly to
the adipose tissue is a superior approach compared to the oral route. Finally,
HPLC of epididymal fat extracts indicated that 98% of the resveratrol was released
after two weeks with 99% released after 5 weeks. The similarities in performance
between the blank scaffolds and those engineered for resveratrol delivery, coupled
with the finding that only 2% of the drug remains after two weeks, suggest that
modifying the scaffold to slow resveratrol delivery and extend its residence in the
tissue may improve overall efficacy and extend the therapeutic window. In addition,
further unraveling the cellular and molecular players that underly how scaffolds
that are not modified with resveratrol improve metabolic health in diet induced
obese mice is expected to inform the design of the next generation of
bioengineering platforms to control adipose tissue function for the treatment of
metabolic disease.
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CHAPTER 4
IMPLANT OF RESVERATROL SCAFFOLDS INTO THE
EPIDIDYMAL ADIPOSE TISSUE ACCELERATES THE RECOVERY
FROM DIET INDUCED OBESITY WHEN COMBINED WITH A
SWITCH TO A NORMAL DIET.
4.1.

Introduction.
Rates of obesity have steadily increased over the past decade with nearly

half of adults projected to be classified as obese by 20303. During obesity, excess
caloric intake results in the rapid expansion of the adipose tissue, however this
expansion proves to be detrimental to the proper functioning of the tissue. The
adipose tissue in obese individuals becomes dysregulated, resulting in secretion
of fatty acids and inflammatory cytokines into the bloodstream where they
accumulate in undesired tissues such as the skeletal muscle and liver83. The
dysregulation of the adipose tissue represents a mechanistic link between obesity
and its associated comorbidities and comortalities. Of all the associated disease
states associated with obesity, none is as tightly linked as type 2 diabetes. Over
90% of type 2 diabetes are also obese highlighting the connection between the
two conditions10.
Current treatments for obesity revolve around lifestyle changes such as diet
and exercise. However, many patients fail to strictly adhere to these lifestyle
changes. Reasons for non-compliance are multifactorial, some of the more
commonly cited complaints from patients include a lack of motivation, failure to see
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noticeable progress, and the inability to adhere to therapies due to a physical
injury19,20. Due to these reasons and more, the success of lifestyle changes in
treating obesity associated type 2 diabetes has been estimated to be as low as
10%20. This highlights a need for the develop treatment platforms that help
promote the shift from an obese to lean state.
Our lab is currently investigating the use of drug delivery from polymer
scaffolds implanted into the adipose tissue as a method to correct the dysfunction
in the adipose tissue brought on by obesity. These scaffolds are made out of
poly(lactide-co-glycolide) an FDA approved biomaterial and the scaffolds alone
have been shown to protect mice from obesity and glucose intolerance91. To
improve upon these effects, resveratrol, a natural polyphenol shown to have lipid
reducing effects was encapsulated within the polymer matrix of our scaffolds.
Previous studies have demonstrated that incorporation of resveratrol extends the
protective effects of the scaffold implant, however little is known about how well
they combine with healthy dietary changes. This is important for two reasons: (1)
in the clinical setting pharmacological treatments are prescribed alongside lifestyle
changes such as diet and exercise and (2) previous studies have shown
dysregulation of the adipose tissue persists even after healthy lifestyle changes
occur112. Therefore, the current study will investigate the ability of resveratrol
scaffolds to restore the adipose tissue to a healthy state when combined with a
switch from a high fat diet, which induces obesity and glucose intolerance, to a
normal diet.
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4.2.

Methods.

Particle Fabrication.
Particles were produced by an oil-in-water emulsion-solvent evaporation
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma)
and ethanol (Sigma) containing 6% w/v PLG (purchased from Evonik, 75:25 mol
ratio lactide to glycolide, 0.76 dL/g) and 10mg/mL of resveratrol (Sigma). The
aqueous phase consisted of 1% w/v poly(vinyl alcohol) (Sigma) dissolved in
ultrapure water. The oil phase was homogenized with the aqueous phase using a
1:7 volume ratio with a benchtop homogenizer. The emulsion was then
immediately added to ultrapure water and stirred for 5 hours to allow particles to
harden and organic solvents to evaporate. Particles were collected via
centrifugation, washed with ultrapure water, and lyophilized.
Scaffold Fabrication.
Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl
particles in a 1:30 ratio and the mixture was then pelleted in a die. Scaffolds were
gas-foamed using 800 psi CO2 at room temperature in a pressure vessel. The salt
porogen was removed by washing in ultrapure water. Complete salt removal was
confirmed by scaffold weight and microscopy. Scaffolds that did not contain
resveratrol were fabricated from particles produced using an oil phase that did not
contain resveratrol or ethanol. From here on resveratrol loaded scaffolds are
referred to as “resveratrol scaffolds” and scaffolds that do not contain resveratrol
are referred to as “blank scaffolds”.
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Quantification of Resveratrol within Scaffolds.
Resveratrol scaffolds were dissolved in dimethyl sulfoxide (DMSO) and
samples were loaded into a UV-StarÒ 96 well plate (Greiner Bio-One) and
scanned for absorption at 330 nm using a Biotek Synergy 2 plate reader.
Resveratrol content was determined with an 8-point standard curve produced by
making ½ dilutions of a 1 mg/mL resveratrol solution in DMSO. All resveratrol
standards contained PLG at the same concentration as the scaffold samples.
Animal Studies.
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks
of age. All animals were housed with ad libitum access to water and food in a
temperature-controlled room with a 12:12 h light:dark cycle. All procedures were
performed in accordance with NIH Guidelines for Care and Use of Animals and
were approved by the Institutional Animal Care and Use Committee at the
University of South Carolina. Mice were allowed to acclimate for two weeks prior
to study.
High Fat Diet Feeding.
After two weeks of acclimation, mice were placed on a 60% high-fat diet
(Research Diets D12492) while a control group was kept on a normal diet (Teklad
8904). On a caloric basis, the high-fat diet consisted of 60% fat from lard, 20%
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet
contained 12% fat, 66% carbohydrate, and 22% protein (total 3.0 kcal/g). Mice
were switched to the normal diet at the time of scaffold implantation and remained
on the diet for the remainder of the experiment.
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Scaffold Implantation.
Mice received scaffold implants into the epididymal fat as previously
described31. Briefly, mice were anesthetized with a 2% mixture of isoflurane and
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile
fashion. Following a lower abdominal midline incision, scaffolds were wrapped in
each epididymal fat pad. The abdominal wall was then closed with a running stitch,
and the skin was closed with wound clips. All mice received two scaffolds per fat
pad (4 scaffolds per mouse).
Intraperitoneal Glucose Tolerance Test.
Mice were fasted for 6-hours before receiving injections of D-glucose into
the peritoneal cavity. Glucose administered was normalized to the body weight (2g
glucose per kg body weight). Blood samples were collected via a tail vein prick at
0, 15, 30, 60, 90, and 120 minutes after glucose administration. Glucose
measurements were obtained using a handheld glucose meter (Accu-Chek Nano,
SmartView).
Food Intake Measurements.
Food was weighed at the beginning and end of each week and the total
grams of food consumed was calculated. To obtain kcal per mouse, weight of food
consumed was normalized by the number of mice in the cage and multiplied by
the calorie density in the food (5.24 kcal/gram).
Western Blotting.
Tissue samples were homogenized in RIPA buffer (Thermo Scientific)
supplemented with protease inhibitor cocktail (Thermo Scientific), phospho-stop
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(Roche), and phenylmethane sulfonyl fluoride (Sigma). Following homogenization,
protein was isolated via centrifugation at 18,000 g for 45 minutes. Protein
concentrations were determined using a BCA assay (Thermo Scientific). Lysates
(30 ug adipose tissue, 100 ug gastrocnemius, and 25 ug liver) were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then
transferred to a nitrocellulose membrane (GE Healthcare Life Sciences) and
incubated with appropriate antibodies. Secondary antibody was a horseradish
peroxidase (HRP)-conjugated antirabbit immunoglobulin G (IgG) grown in goat
(Abcam). Proteins were then visualized using SuperSignal West Pico substrate
(Thermo Scientific). Antibodies to total Akt, phospho-Akt ser 473, ATGL, and
GAPDH were purchased from Cell Signaling Technology (1:1000 dilution). The
antibody for Glut4 was purchased from Sigma Aldrich (1:1000 dilution). The
antibody for CPT1A was purchased from Abcam (1:1000 dilution). The antibody
for arginase 1 was purchased from Santa Cruz Biotechnology (1:250 dilution).
Enzyme Linked Immunosorbent Assay.
Adipose tissue protein was isolated as described in the section
above. ELISA was used to determine mg of analyte per mg of adipose tissue. All
ELISA kits were purchased from R & D Systems and were performed following the
manufacturer’s instructions.
Histological Staining and Immunohistochemistry.
Adipose tissues were harvested, fixed in 4% paraformaldehyde, embedded
into paraffin, and 7µm sections were cut and mounted on slides. Sections were
either stained with Hematoxylin and Eosin for adipocyte size analysis using ImageJ
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or

stained

for

proteins

of

interest

using

immunohistochemistry.

For

immunohistochemistry, antigen retrieval was performed using citrate buffer with a
pH of 6.0. Slides were then block in a solution of 10% goat serum, 1% BSA and
an anti-CD16/32 fc block at a concentration of 10µg/mL for one hour. Primary
antibodies were purchased from Abcam. Immunohistochemistry was visualized
using an anti-rabbit polymer secondary antibody and chromogen solution
purchased from Dako.
Statistical Analysis.
Data is presented as mean ± standard error of the mean. All statistical
analyses were conducted using Prism software version 7 (GraphPad). Data sets
comparing three or more groups were analyzed using a one-way ANOVA with
Tukey’s multiple comparisons test. Data sets comparing two or more groups over
time were analyzed using a two-way ANOVA with Tukey’s multiple comparisons
test. P values less than 0.05 were considered significant.
4.3.

Results.

Characterization of Resveratrol Scaffolds.
Representative scanning electron microscopy images of resveratrol
scaffolds are presented in Figure 4.1. Scaffolds were approximately 5mm in
diameter and 2mm in height with pore sizes ranging from 250-500µm. The
resveratrol content within the scaffolds was measured to be 103 ± 23 µg per
scaffold. Each mouse received 2 scaffolds into each epididymal fat pad for a dose
of 412 ± 92 µg per mouse. Unloaded scaffolds (referred to as “blank scaffolds”
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from this point forward) were identical in dimensions and pore size with the only
difference between the two scaffolds being resveratrol content.

Figure 4.1. SEM Images of PLG scaffolds. Scanning electron microscope images of
a (A) top and (B) side profile of a scaffold. Scaffolds are 5 mm in diameter, 2 mm in
height, with a pore size ranging between 250 and 500 microns. Scale bar is 0.5 mm.

Mice Receiving Resveratrol Scaffold Implants Have Improved Glucose Tolerance
when the High Fat Diet is removed.
Mice were made obese and glucose intolerant through the feeding of a high
fat diet (HFD). After two weeks, the fasting weight of mice on the HFD was
significantly elevated from control mice kept on a normal chow diet (Supplemental
Figure 4.8).

At this time point glucose tolerance was assessed using an

intraperitoneal glucose tolerance test (IPGTT). Correlating with the significant
increase in body weight gain, mice on the HFD had significant elevations in the
area under the curve calculated from the IPGTT (Supplemental Figure 4.8B-C),
indicating glucose intolerance. At this point, mice received either a blank or
resveratrol scaffold. Additionally, a group of mice received the surgical procedure
but no material implant (referred to as sham surgery from this point forward). After
administration of the scaffolds/surgeries, all groups were switched to a normal
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Figure 4.2. The effect of scaffold implant on glucose tolerance. (A) Outline of the
study. (B) Fasting weight, (C) intraperitoneal glucose tolerance test and (D) area under
the curve completed 2 weeks after scaffold implant and change to ND. Statistics were
calculated using a one-way ANOVA with a Tukey’s multiple comparisons test. *p<0.05
versus sham. For all conditions n=4-5 mice.

chow diet for two additional weeks. Fasting weight and glucose tolerance were
assessed after two additional weeks. No difference in fasting weight was detected
between treatment groups, however, both scaffold groups showed improvements
in glucose tolerance during an IPGTT, with mice receiving resveratrol scaffolds
significantly outperforming mice receiving sham surgery (Figure 4.2B-D). Taken
together, the data demonstrates that mice receiving scaffold implants do not show
differences in fasting weight but demonstrate improved glucose tolerance
indicating accelerated recovery from HFD feeding.
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Mice Receiving Scaffold Implants Have Decreased Fat Pad Weight, Adipocyte
Size, and Increased Lipid Metabolism.
In the high fat diet mouse model, the high lipid composition of the food
results in rapid expansion of the adipose tissue in an attempt to store excess lipids

Figure 4.3. The effect of scaffold implant on fat pad weight, adipocyte size, and
lipid metabolism. (A-C) Representative images of formalin fixed paraffin embedded
tissue sections stained with hematoxylin and eosin. Representative images of
adipocytes from mice receiving (A) sham surgery, (B) blank scaffolds, and (C)
resveratrol scaffolds 2 weeks after implant; scale bar is 100 µm. (D) Epididymal fat pad
weights. (E) Quantification of average adipocyte area; n=3 mice per condition. (F)
Representative western blots assessing ATGL and CPT1 in the epididymal fat two
weeks after implant. Quantification of band intensity of (G) ATGL and (H) CPT1. For all
conditions n=4 mice. Statistics were calculated using a one-way ANOVA with a Tukey’s
multiple comparisons test. *p<0.05 versus sham.
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entering the body. When the adipose tissue is no longer able to keep up with the
rapid influx of lipids cause by the diet, they accumulate in peripheral tissues
resulting in glucose intolerance83. Therefore, we suspected the observed
improvements in glucose tolerance might be attributed to increased lipid utilization
in the adipose tissue caused by scaffold implants. In support of this, the weight of
the epididymal adipose tissue of mice receiving scaffold implants was lower
relative to sham surgery controls, with mice receiving blank scaffolds achieving
statistical significance (Figure 4.3D). Because adipose tissue size is largely
dictated by the cell’s lipid stores, we then assessed the average size of the
adipocytes in the epididymal adipose tissue, using ImageJ analysis of adipose
tissue sectioned stained with hematoxylin (Figure 4.3A-C). Interestingly, the
average adipocyte size in epididymal fat pads implanted with both blank and
resveratrol scaffolds was significantly lower relative mice receiving a sham surgery
(Figure 4.3E). Finally, levels of ATGL, a marker of lipolysis, and CPT1, a marker
of fatty acid oxidation was assessed at the implant site, however, no significant
changes were detected at this time point (Figure 4.3F-H). Taken together this data
suggests scaffold implant leads to a reduction in the size of the epididymal adipose
tissue and this is achieved in part through a decrease in the lipid content within the
adipocytes.
Scaffold implant into the epididymal adipose tissue recruits’ cells expressing CPT1
into the tissue.
Though western blot did not reveal any significant changes in CPT1
expression, the decrease in adipocyte size suggests alterations in lipid metabolism
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within the tissue are occurring. To better understand which cells types were
responsible for these changes, we stained sections of the epididymal adipose
tissue from each of our treatment groups for CPT1 using immunohistochemistry.
Interestingly, the cells that showed the highest amount of CPT1 expression were
not the adipocytes, but cells associated with the host located in an around the
scaffold (Figure 4.4). Upon closer inspection, many of the cell types most heavily
expressing CPT1 were the multinucleated giant cells that were in direct contact
with the polymer. Overall this data suggests that scaffold implant recruits cells

Figure 4.4. Scaffold implant recruits’ cells expressing CPT1 to the epididymal
adipose tissue. Representative images of immunohistochemistry staining for CPT1 in
the epididymal adipose tissue in mice receiving a sham surgery, blank scaffold implant
or resveratrol scaffold implant. Top three images are taken at 4x, scale bar represents
500µm. Bottom three images are taken at 40x, scale bar represents 100µm.

highly expressing CPT1, a marker of fatty acid oxidation to the adipose tissue, a
tissue that is filled with fatty acids. These multinucleated giant cells could play a
role in the ability of scaffolds to reduce adipocyte size and overall fat mass.
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Multinucleated giant cells expressing CPT1 also express anti-inflammatory
macrophage markers.
It has been well documented that alternatively activated macrophages
preferentially burn fatty acids as energy64. As multinucleated giant cells are the

Figure 4.5. Multinucleated giant cells co-express anti-inflammatory markers
arginase-1 and CD206. (A) Western blot assessing arginase-1 and CD206 levels in
the epididymal adipose tissue 2 weeks after scaffold implant. Quantification of band
intensity of (B) arginase-1 and (C) CD206. For all conditions n=4 mice. Statistics were
calculated using a one-way ANOVA with a Tukey’s multiple comparisons test. *p<0.05
versus sham. †p<0.05 versus resveratrol scaffold. (D) Representative images of
immunohistochemistry staining for arginase-1 and CD206 in the epididymal adipose
tissue in mice receiving blank scaffold or resveratrol scaffold implants. Images are
taken at 40x, scale bar represents 100µm.
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result of a fusion of multiple macrophages, we sought to investigate their
expression of anti-inflammatory macrophage markers arginase-1 and CD206 to
support their use of fatty acids as energy. CD206 expression did not shown any
significant changes between any of the groups (Figure 4.5A). However, western
blot analysis revealed stark elevations in the anti-inflammatory marker arginase-1
in both blank in resveratrol scaffolds with expression in blank scaffolds being
significantly higher than their drug loaded counterparts. To better understand the
cell types expressing these markers, immunohistochemistry staining for these
markers was performed. Similar to the results of CPT1, the major cell population
staining positive for CD206 and arginase-1 were the multinucleated giant cells
directly interacting with the polymer scaffold matrix. Interestingly, giant cells in
contact with the blank scaffold seemed to have higher expression of arginase-1
relative to those in contact with resveratrol scaffolds. Taken together this data
suggests that multinucleated giant cells that highly express CPT1 also express an
anti-inflammatory immune cell profile further suggesting they are participating in
lipid consumption within the adipose tissue.
Mice Receiving Scaffold Implants Have Increased Expression of Proteins that
Regulate Glucose Uptake in the Adipose Tissue.
A decrease in the area under the curve during an IPGTT suggests that
implant of scaffolds could be altering glucose uptake. To test this hypothesis,
glucose transport molecules were assessed at the implant site. In the adipose
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Figure 4.6. Effect of scaffold implant on insulin signaling and glucose transport
in the epididymal fat. (A) Western blot assessing Glut1, pAkt, and Glut4 levels in the
epididymal adipose tissue 2 weeks after scaffold implant. Quantification of band
intensity of (B) Glut1, (C) pAkt, and (D) Glut4. Statistics were calculated using a oneway ANOVA with a Tukey’s multiple comparisons test; * indicates p<0.05 versus sham.
For all conditions n=4 mice.

tissue, glucose uptake is mainly facilitated by glucose transporter 4 (Glut4), which
is responsible for insulin stimulated glucose transport113. Additionally, glucose can
be taken up independent of insulin stimulation through glucose transporter 1
(Glut1)46,48.

Insulin

dependent

transport,

measured

through

levels

of

phosphorylated Akt which promotes Glut4 expression after insulin binds to its
receptor, and Glut4 expression, was unchanged between all groups (Figure 4.6CD). However, Glut1 was significantly elevated in the epididymal adipose tissue of
mice receiving both blank and resveratrol scaffolds (Figure 4.6B). Taken together
this data demonstrates that implant of scaffolds and not incorporation of
resveratrol, results in the elevation of makers of insulin independent glucose
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transport and this effect correlates with improved glucose tolerance measured
during the intraperitoneal glucose tolerance test (Figure 4.2F-G).
Immune cells recruited to the adipose tissue by scaffold implant show high levels
of Glut1 expression.
To better understand the cell types responsible for elevated Glut1 within the
adipose tissue, immunohistochemistry was used to stain for Glut1 within the
implant site (Figure 4.7). Similar to CPT1, Glut1 was most expressed in the cells
recruited to the adipose tissue by scaffold implant. The highest expression of Glut1

Figure 4.7. Cells recruited to the adipose tissue by scaffold implant express high
levels of Glut1. Representative images of immunohistochemistry staining for Glut1 in
the epididymal adipose tissue in mice receiving a sham surgery, blank scaffold implant
or resveratrol scaffold implant. Top three images are taken at 4x, scale bar represents
500µm. Bottom three images are taken at 40x, scale bar represents 100µm.

was observed in the multinucleated giant cells that were in direct contact with the
scaffold. Correlating with western blot analysis, no obvious differences in
expression of Glut1 could be seen between blank and resveratrol scaffold groups.
Taken together this data suggests that cellular infiltration into the adipose tissue
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due to scaffold implant is responsible the elevation of Glut1 expression within the
tissue and this increase in glucose burning cells could represent a mechanism
behind improved glucose tolerance observed during the IPGTT.
4.4.

Discussion.
The goal of this research was to investigate the ability of resveratrol loaded

scaffolds to improve glucose tolerance and decrease fat mass when accompanied
by a diet swap from a high fat diet to a normal diet. Two weeks after the initial
feeding of the high fat diet, mice showed significant elevations in body weight and
the area under the curve calculated from an intraperitoneal glucose tolerance test,
indicating impaired glucose uptake in peripheral tissues at this time point.
Supporting this data are previous studies demonstrating that the whole animal and
importantly, the adipose tissue are dysregulated at this time point83.
Implant of the scaffolds showed significant improvements in both adipose
tissue weight and glucose tolerance relative to sham surgery controls. Additionally,
the scaffold implant lead to a reduction in average adipocyte size which has been
demonstrated to be correlated with healthy adipose tissue function114. When
investigating the cells responsible for these changes we found that cells recruited
to the epididymal fat by scaffold implant express high levels of CPT1, Glut1,
Arginase 1, and CD206. Expression of these markers indication that these cells
are anti-inflammatory and have a high appetite for both glucose and fatty acids.
Based on this data, we propose that scaffolds recruit cells to the epididymal
adipose tissue where due to the foreign body response. These cells require fuel in
the form of both lipids and glucose to fuel their mechanisms to break down the
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polymer matrix. This increases the utilization of glucose and fatty acids in the
adipose tissue and prevents ectopic accumulation of lipids in peripheral tissues
such as the skeletal muscle and liver, saving insulin signaling in these tissues.
4.5.

Supplemental Data.

Figure 4.8. Weight and glucose tolerance of mice after two weeks of HFD feeding.
(A) Fasting weight, (B) intraperitoneal glucose tolerance test and (C) area under the
curve assessed in mice after two weeks of high fat diet feeding. Statistics were
calculated using an unpaired t-test; *p<0.05 versus vs HFD. For ND n=5 mice, for HFD
n=15 mice. ND = normal diet and HFD = high fat diet
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CHAPTER 5
CONCLUDING REMARKS AND FUTURE DIRECTIONS
5.1.

Concluding Remarks
Dysregulation of the adipose tissue provides a mechanistic link between the

obese and type 2 diabetic disease states. With the number of individuals suffering
from obesity associated type 2 diabetes ever rising, therapeutic platforms designed
to specifically target, and correct adipose tissue dysfunction could prove to be
promising at treating this large patient population. The primary objective of our
work was to understand if delivery of therapeutic agents directly to the adipose
tissue from biomaterial scaffolds, represents a promising platform to correct fat
gain and glucose intolerance, two major concerns in the obese type 2 diabetic
population.
The first step towards accomplishing this objective focused on fully
understanding the effects of our drug delivery vehicle, porous poly(lactide-coglycolide) scaffolds, on adipose tissue function, fat storage, and glucose uptake
independent of drug loading (Chapter 2). This led to the novel discovery that the
host response to poly(lactide-co-glycolide) scaffolds implanted into the adipose
tissue decreased in tissue weight and fat content and elevated glucose uptake in
tissue. Even more impactful was the ability to observe this effect on the systemic
level through a decrease in fasting blood glucose. The polymer scaffolds were next
tested in a mouse model of diet induced obesity and glucose intolerance. Implant
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of scaffolds into the adipose tissue resulted in decreased fat mass not just
in the site of implant but in distant fat depots, demonstrating an ability to influence
fat storage at a global level. Additionally, the mice were protected from glucose
intolerance. The ability of poly(lactide-co-glycolide) scaffolds to achieve the
primary goals of reduced fat content and improved glucose tolerance independent
of drug loaded clearly demonstrates potential as therapeutic devices to treat
obesity associated type 2 diabetes.
The next step towards achieving our objective was to attempt to augment
the effects of the polymer scaffolds through the incorporation of resveratrol into the
polymer matrix for direct delivery to the adipose tissue. This was accomplished by
encapsulating resveratrol into the poly(lactide-co-glycolide) microparticles during
the single emulsion step. Resveratrol was successfully incorporated into the
scaffold and could be reproducibly loaded at similar concentrations. The ability of
resveratrol loaded scaffolds to protect mice against glucose intolerance and fat
gain was assessed using the same mouse model of diet induced obesity (Chapter
3). Resveratrol loaded scaffolds showed improvement over blank scaffolds at
preventing fat gain and improving glucose intolerance, significantly improving both
metrics 5 weeks after administration. Additionally, resveratrol was still detected in
the adipose tissue 5 weeks after implant, demonstrating the ability of scaffolds to
release a drug payload for an extended period of time.
Finally, the ability of resveratrol scaffold implants to combine with a change
from a high fat diet to a normal diet, simulating a combination therapy with lifestyle
changes, was investigated in Chapter 4. It was found that implant of resveratrol
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loaded scaffolds into the adipose tissue resulted in the accelerated recovery from
high fat diet feeding relative to control groups. Similar to previous studies these
mice showed reduced fat content and improved glucose tolerance. Additionally,
these studies led to the discovery that multinucleated cells that closely surround
the polymer scaffold express high levels of markers for lipid metabolism and an
anti-inflammatory phenotype. These cells could represent one of the mechanisms
behind the protective effect of both resveratrol and blank scaffold implants.
In summary, the novel contributions to the field can be summarized in three
key points. Firstly, these studies demonstrate a protective effect of the host
response to a polymer scaffold implanted into the adipose against a model of
obesity associated type 2 diabetes, which has never before been reported.
Secondly, this work reveals that implant of polymeric scaffolds into the adipose
tissue has the ability to modulate glucose uptake to a degree where it can be
detected on the systemic level. Finally, through the incorporation of small
molecules into the polymer matrix of the scaffold, the therapeutic effects of these
can be improved upon and combine well with lifestyle changes. Together this
research forms the foundation of a new therapeutic platform for treatment of
obesity associated type 2 diabetes.
5.2.

Future Directions
The work outlined in this dissertation clearly demonstrates the therapeutic

potential of using poly(lactide-co-glycolide) scaffolds implanted into the adipose
tissue to treat obesity associated type 2 diabetes. Furthermore, the incorporation
of resveratrol into the polymer matrix of the scaffold augments the effects beyond
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the unloaded scaffold. However, despite this work demonstrating the promise of
this approach, there is still room for improvement. Based on the knowledge gained
thus far there are three areas in particular that will lead to the advancement of this
therapeutic strategy. The first and likely largest obstacle is overcoming the
invasiveness of the procedure required to implant the polymer scaffolds. Currently,
the implant procedure requires the abdominal cavity to be opened and the incision
required for the scaffold implant is large relative to the size of the animal. One path
to reduce invasiveness would be for future studies to investigate if the protective
effects observed in these studies can be reproduced when scaffolds are implanted
into subcutaneous fat pads. This would allow for scaffolds to be delivered via a
trocar needle, significantly reducing complications associated with the implant
procedure. Alternatively, investigating if polymer particles could be an appropriate
substitute for the scaffolds is another way to reduce invasiveness. The use of the
microparticles would allow administration via injection, again significantly reducing
the invasiveness of the procedure.
The second method of improving scaffold-based delivery of therapeutics to
the adipose tissue is to investigate ways to extend the release of the drug
encapsulated within the polymer. While resveratrol was able to be successfully
detected in the adipose tissue 5 weeks after implant, only 1% of the total
resveratrol delivered remained at this timepoint. Importantly, when we investigated
the amount of resveratrol remaining in the scaffold after the two-week timepoint,
only 2% of the initial drug payload was detected in the adipose tissue, suggesting
that there is a rapid release of the majority of the drug payload that occurs within
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the first two weeks (and more likely the first few days) followed by an extended
release of the remaining drug payload. Ideally, the drug would be released
consistently over time. Ways to improve upon the release could lie in adjusting the
porosity of the polymer. The pore size of the scaffolds used in these studies ranged
from 250-500µm. This pore size was chosen so adipocytes which are on the order
of 100µm could freely interact with the scaffold. However, the histological analysis
revealed that immune cells, which are on the order of 10-20µm, and not adipocytes
are in closest contact with the polymer. These cells function to break down the
polymer leading to the accelerated release of the drug payload into the tissue as
the polymer matrix is degraded. By reducing the pore size, it will take longer for
the immune cells to penetrate into the scaffold which could result in a slower
release of the drug payload.
Finally, while the incorporation of resveratrol into the polymer matrix did
show improvements in fat reduction and glucose tolerance relative to the unloaded
polymer scaffolds, the impartments were modest. Resveratrol was selected for
these studies due to the molecule’s promise in in-vivo animal models of obesity
and the drawback of its rapid metabolism in the blood stream. However, resveratrol
lacks potency. Investigating more potent drugs such as those already approved by
the FDA for treating obesity and diabetes could prove to be a more fruitful endeavor
than using natural compounds. Importantly, the techniques used in these studies
to incorporate resveratrol into the polymer matrix of the scaffolds can be easily
translated to a variety of compounds. The investigation of these avenues could
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lead to the development of the next generation of polymer scaffolds for the
treatment of obesity and obesity related type 2 diabetes.
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APPENDIX A
BEST PRACTICES FOR THE HIGH FAT DIET MOUSE MODEL OF
DIET INDUCED OBESITY AND INSULIN RESISTANCE
The high fat diet mouse model of diet induced obesity has been utilized for
decades to study weight gain and glucose intolerance. There are several well
written papers on the animal model the researcher should become familiar with
before beginning a high fat diet animal study115–119. In addition, the following
section will outline in detail the tips and recommendations for carrying out a high
fat diet mouse study accumulated during my Ph.D. research.
Ordering Mice.
Mice should be ordered from the Jackson Laboratory. The mice used for
these studies are male C57BL/6 mice. For the studies outlined in this dissertation,
5-week-old mice were purchased. One drawback for choosing mice of this age is
that they are still developing at this time period, which can complicate the
interpretation of the results. Future studies should consider using mice 12 weeks
or older to remove this additional variable as they are fully developed by this
time120. Based on previous research, it is suggested that the housing density
should be three mice per cage as it has been shown to reduce aggression121. It is
important to consider the delivery schedule of the mice when planning a high fat
diet animal study. Orders for mice from Jackson Laboratory must be placed with
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the Animal Resource Facility by Thursday at 2:00 pm. Mice then arrive the
following Thursday exactly one week later.
One-week acclimation period.
Upon arrival to the animal facility, mice will require a one-week acclimation
period to adjust to their new environment. It is important that during this time the
researcher does not handle the mice as it will increase the stress levels of the mice
and could lead to aggressive behavior and poor data reproducibility in subsequent
experiments. However, the one-week acclimation period should be used to ensure
all materials needed for future sample and data collection are ordered and in the
lab.
One-week handling period.
After the one-week acclimation period, the following week should be used
to adjust mice to human handling. This period is essential to ensure that no
unnecessary stress is placed on the mice when performing handling intensive
procedures such as intraperitoneal glucose tolerance tests. During this week, the
researcher should:
1. Handle and scruff all mice daily.
2. Label mice with ear punches to indicate number.
3. Acquire baseline measurements of fasting weight and glucose.
4. Acquire baseline DEXA and IPGTT measurements.
It is recommended to take baseline DEXA scans prior to measurements of fasting
weight, fasting glucose and the IPGTT. The reasoning for this is twofold. First, the
total weight gain during high fat diet feeding is attributed mostly to an increase in
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fat mass, which can account for 30-60% of the total body weight of high fat diet fed
mice115. However, the majority of glucose uptake occurs in lean tissue such as the
skeletal muscle and brain, therefore administering glucose during an IPGTT based
on total body weight can result in disproportionally large glucose doses relative to
glucose utilizing tissue. For this reason, it is recommended to administer glucose
in proportion to lean mass measured by DEXA scans, requiring them to be
completed prior to the IPGTT. Secondly, measuring weight, blood glucose, and the
IPGTT all require fasting. The optimal fasting time for these measurements has
been shown to be 6 hours because overnight fasts can result in muscle catabolism
and 4 hour fasts do allow enough time for blood glucose levels to stabilize115.
Multiple 6-hour fasts will put unnecessary stress on the mice and reduce overall
food consumption hindering the progression of the diet, therefore, it is
recommended that fasting measurements for body weight, blood glucose, and the
IPGTT are completed on the same day allowing for one fast per week. Because
DEXA scans are needed to calculate glucose dosage for the IPGTT, they should
be completed before all fasting measurements.
High fat diet feeding and acquisition of baseline measurements.
It has been well established that one week of high fat diet feeding results in
significant increases in fat mass and insulin resistance83. Because the goals of the
research in this dissertation were focused around treating these two conditions,
only one week of high fat diet feeding was completed prior to administering
treatments. However, should future studies aim to address conditions such as
inflammation or hyperinsulinemia, it will be necessary to keep the mice on the high
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fat diet for longer periods of time (~8 weeks) to allow these conditions to occur122.
One important consideration for beginning the high fat diet stage of the animal
study is that the mouse cages should be changed out upon the switch from the
normal diet to the high fat diet. Mice are known to hide their food in the bedding of
their cage therefore changing out the cages ensures that the mice will only have
access to the high fat diet allowing the effects of the model to begin immediately.
Tips for Performing the Intraperitoneal Glucose Tolerance Test.
During the intraperitoneal glucose tolerance test, mice are fasted for 6hours before receiving injections of D-glucose into the peritoneal cavity. It is critical
to place mice in a clean cage during the fasting period of this procedure. As
mentioned above, mice are prone to hiding food in their bedding. Failing to place
the mice in a new cage would still allow access to this food and could prevent blood
glucose measurements from being collected during the fasted state. Blood glucose
measurements are collected via the end of the tail. Collecting blood from this site
requires the tip of the tail to be removed using a sterile razor. It was found that
removing approximately 2mm off the end of the tail is optimal for this procedure,
allowing for easy blood collection throughout the experiment while minimizing the
stress on the mouse. Because removing the end of the tail places stress on the
mouse, which can lead to aggression and inconsistent blood glucose
measurements, it is recommended to allow mice to rest in the cage for a minimum
of 30 minutes after the end of the tail is removed. Glucose is then administered
normalized to the lean mass (2g glucose per kg of lean mass). Blood samples are
collected at 0, 15, 30, 60, 90, and 120 minutes after glucose administration.
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Because measurements are time sensitive it is not recommended that a
researcher complete this task alone, as collecting and recording glucose
measurements from many mice is time intensive. At minimum there should be two
researchers, one collecting the glucose measurements and one recording them.
Additional Considerations for performing a High Fat Diet Animal Study.
There are two animal facilities utilized for the lab’s animal studies: The
Discovery animal facility and the Graduate Student Resource Center (GSRC)
animal facility. DEXA scans are performed at the Discovery animal facility,
however, this facility has issues keeping the 12-hour light and dark cycles.
Specifically, there have been instances when lights in a room are kept on for 24
hours. As mice are nocturnal, the failure of a proper dark cycle causes additional
stress and has resulted in difficulty in obtaining reproducible blood glucose
measurements. Therefore, if possible, it is recommended that mice kept at
Discovery are only used for body composition measurements. Additionally,
keeping mice in rooms that are heavily utilized will allow for problems to be
identified and resolved more efficiently.
For both the Discovery and GSRC facilities, it is beneficial to keep an open
dialogue with the animal facility staff. Animal facility staff is responsible for ensuring
mice are well fed and cages are changed weekly. However, the researcher is
responsible for administering the high fat diet. If food levels run low, the staff will
be forced to give the mice normal chow to keep them healthy. A change in diet will
prevent any data from being properly interpreted and essentially ruin the
experiment. To prevent this, fresh food should be given to the mice once a week
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at minimum. It was found that approximately 150g of food will be sufficient to feed
three mice for a week. In the event that food stores run low, requesting that the
staff contact the researcher prior to changing the mice to a normal diet is beneficial.
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APPENDIX B
BEST PRACTICES FOR THE FABRICATION OF POLY(LACTIDECO-GLYCOLIDE) SCAFFOLDS
Fabricating scaffolds for implant into mice requires forethought and
planning to ensure scaffolds are completely leached and properly analyzed prior
to the time of surgical implant. Additionally, over the course of my doctoral research
there has been many challenges in fabricating reproducible scaffolds. This section
will outline tips and recommendations for the scaffold fabrication process.
The first, and most important, consideration when fabricating scaffolds is
humidity. We found that fabricating scaffolds during humid conditions lead to poor
coating of the polymer particles around the salt crystals. This leads to the
fabrication of inconsistent scaffolds (and drug loading if the polymer contains a
therapeutic agent) and should be avoided. To solve this issue, a dehumidifier and
humidity monitoring system has been placed in the room where scaffolds are
fabricated. The dehumidifier should be turned on 24 hours prior to scaffold
fabrication. However, the dehumidifier cannot properly lower the humidity of the
room with the air conditioning unit on and cycling fresh humid air into the room,
therefore the air conditioning unit must be turned off prior and during the scaffold
fabrication process. It was found that lowering the humidity in the scaffold
fabrication room to below 40% is adequate for scaffold fabrication.
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The second major consideration when fabricating scaffolds is the leaching
process. To remove the salt crystals after the gas foaming process, scaffolds are
leached in deionized water. It is important to ensure all salt is removed from the
scaffolds prior to implant into the adipose tissue. Salt removal is assessed by the
weight of the scaffolds. However, to gain an accurate measurement of scaffold
weight, they must be completely dried of all water, which takes a minimum of 24
hours when placed in a desiccator. Multiple leaching and drying cycles are
necessary to determine if the salt is completely removed from the polymer matrix;
therefore, scaffolds should be fabricated weeks before the date of the surgery.
Additionally, it was found that the incorporation of resveratrol into the polymer
matrix increased the number of leaching cycles needed to completely remove the
salt crystals. A possible explanation is the incorporation of resveratrol increased
the overall hydrophobicity of the scaffold, increasing the time required for the water
to permeate thorough the scaffold and remove the salt. Based on this, it would be
wise to assess the leaching time for scaffolds containing new small molecules well
before they are needed for animal studies.
Originally, scaffolds were fabricated individually. This process involved
weighing out the polymer and salt required to make one scaffold into an Eppendorf
tube and mixing the contents of each tube manually with a small drill bit. Not only
was this method time intensive, requiring the precise weighing of small masses
(2.5mg of polymer and 75mg of salt), but the scaffolds produced from this method
had lower than expected weights with high variability. The variation in weight was
due to inconsistent coating of the polymer around the salt crystals as the quality of
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mixing changed between each scaffold. To overcome this issue, a new fabrication
technique was developed to allow scaffolds to be made in “batches.” For this
method, material for multiple scaffolds is weighed into a single 2mL Eppendorf
tube. The polymer and salt are then mixed by inverting the tube several times over
the course of five minutes. Next, enough pre-mixed polymer and salt for a single
scaffold (77.5mg) is weighed out and the scaffold fabrication procedure is
completed. Scaffolds made using this method were found to have better coating,
reflected by higher average weights, and lower variability. One important
consideration is to weigh out enough polymer for 2 more scaffolds than desired.
Some polymer and salt are lost during the weighing process, weighing out material
for 2 additional scaffolds will account for this loss.
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